

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Phase III, international, multi-centre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: A JORTC-PAL16 Trial Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050182
Article Type:	Protocol
Date Submitted by the Author:	13-Feb-2021
Complete List of Authors:	<p>Matsuoka, Hiromichi; National Cancer Center Japan, Clark, Katherine Fazekas, Belinda; University of Technology Sydney, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation) Oyamada, Shunsuke; Japanese Organisation for Research and Treatment of Cancer, Biostatistics Brown, Linda; University of Technology Sydney, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation) Ishiki, Hiroto; National Cancer Center Japan, Matsuda, Yoshinobu; National Hospital Organization Kinki-Chuo Chest Medical Center, Hasuo, Hideaki; Kansai Medical University Hirakata Hospital, Psychosomatic medicine Ariyoshi, Keisuke; Institute of Medical Science, The University of Tokyo, Palliative Medicine Lee, Jessica Le, Brian; Royal Melbourne Hospital Allcroft, Peter Kochovska, Slavica; University of Technology Sydney Faculty of Health, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation) Fujiwara, Noriko Miyaji, Tempei; University of Tokyo, Department of Clinical Trial Data Management, Graduate School of Medicine Lovell, Melanie; Greenwich Hospital, Palliative Care Agar, Meera ; University of Technology Sydney, Centre of Cardiovascular and Chronic Care, Faculty of Health Yamaguchi, Takuhiro; Division of Biostatistics, Satomi, Eriko Iwase, Satoru; Institute of Medical Science, The University of Tokyo,, Department of Palliative Medicine Phillips, Jane; University of Technology Sydney, Faculty of Health Koyama, Atsuko; Kindai University Faculty of Medicine, Currow, David ; University of Technology Sydney, ; Cancer Institute New South Wales,</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	Adult palliative care < PALLIATIVE CARE, Cancer pain < ONCOLOGY, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

STUDY PROTOCOL

Phase III, international, multi-centre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: A JORTC-PAL16 Trial Protocol

Matsuoka H ^{1,2}, Clark K ², Fazekas B ², Oyamada S ³, Brown L ², Ishiki H ¹, Matsuda Y ⁴, Hasuo H ⁵, Ariyoshi K ³, Lee J ^{2,6}, Le B ², Allcroft P ², Kochovska S ², Fujiwara N ⁷, Miyaji T ⁸, Lovell MR ^{2,9}, Agar M ², Yamaguchi T ¹⁰, Satomi E ¹, Iwase S ¹¹, Phillips J ², Koyama A ¹², Currow DC ²

1. National Cancer Centre Hospital, Tokyo, Japan
2. IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia
3. Japanese Organisation for Research and Treatment of Cancer (JORTC), NPO, Tokyo, Japan
4. Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan
5. Palliative Care Centre, Kansai Medical University, Osaka, Japan
6. Concord Centre for Palliative Care, Concord Hospital, Sydney, NSW, Australia
7. The Institute of Medical Science, The University of Tokyo
8. Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
9. HammondCare, Greenwich Hospital, Greenwich NSW Australia

1
2
3
4
5
6 10. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai,
7
8 Japan

9
10
11 11. Department of Palliative Medicine, Saitama Medical University hospital, Saitama,
12
13 Japan

14
15 12. Department of Psychosomatic Medicine, Kindai University Faculty of Medicine,
16
17 Osaka, Japan

18
19
20
21
22 Corresponding Author: Hiromichi Matsuoka

23
24 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

25
26 Tel.: +81-3-3547-5248

27
28 E-mail:hiromima@ncc.go.jp
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Management of cancer patients who experience neuropathic cancer pain (NCP) refractory to regular opioids remains an important challenge. The effectiveness of pregabalin for this population has already been confirmed in two randomised controlled trials (RCTs) compared with placebo, arguably making this a standard of care. Duloxetine offers the potential of analgesia in opioid refractory NCP. However, there are no RCT of duloxetine for the management of opioid-refractory NCP as a first line treatment. Both classes of drug have the potential to reduce NCP, but there has been no head-to-head comparison for the net effect, especially given differing side-effect profiles.

Methods and analysis: An international, multi-centre, double-blind, dose increment, parallel-arm, randomised controlled trial is planned. Inclusion criteria include: adults with cancer experiencing NCP refractory to opioids; Brief Pain Inventory (BPI)-item 3 (worst pain) of ≥ 4 ; Neuropathic Pain on the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (LANSS) of ≥ 12 ; and having had an adequate trial of regular opioid medication (≥ 60 mg/day oral morphine equivalent dose). Patients with chemotherapy-induced peripheral neuropathy (CIPN) are excluded.

The study will recruit from palliative care teams (inpatient and community) in Japan

1
2
3
4
5
6 and Australia. Participants will be randomised (1:1 allocation ratio) to duloxetine or
7
8
9 pregabalin arm. Evaluations will be made at baseline (randomisation), days 0,3,7,14 and
10
11
12 21. The primary endpoint is defined as the difference in BPI item 3 for worst pain
13
14
15 intensity over the previous 24 hours at day 14 between groups. A sample size of 160
16
17
18 patients will be examined between February 2020 and March 2023.
19

20
21 **Ethics and Dissemination:** Ethics approval was obtained at Osaka City University
22
23
24 Hospital Certified Review Board and South Western Sydney Local Health District
25
26
27 Human Research Ethics Committee. The results of this study will be submitted for
28
29
30 publication in international journals and the key findings presented at international
31
32
33 conferences.
34
35
36
37
38

39 Trial registration number: jRCTs051190097, Date of registration: 27 January 2020.

40
41
42 ACTRN12620000656932, Date of registration: 5 June 2020.
43
44
45
46
47

48 **Keywords:** duloxetine, pregabalin, randomised controlled trial, neuropathic cancer
49
50
51 pain, palliative care.
52
53
54
55
56
57
58
59
60

Strengths and limitation of this study

- This is the first study to compare the analgesic effectiveness and harms of duloxetine with pregabalin in patients experiencing neuropathic cancer pain refractory to opioids. The results of the trial will clarify the first-line standard of care for neuropathic cancer pain.
- An international collaborative and adequately powered trial designed to provide a clinically meaningful outcome, and enable the harms following intervention to be prospectively and systematically evaluated.
- Although we have excluded patients with chemotherapy-induced peripheral neuropathy (CIPN) from the study population for accurate evaluation of the pharmacological effects of pregabalin and duloxetine, this study still includes the heterogeneity of other causes of neuropathic cancer pain.
- The primary endpoint is not average pain intensity over the past 24 hours but the difference in worst pain intensity score, which has shown the highest degree of internal consistency for assessing a pain-reduction treatment effect.
- Recommendations for maximum dosing of adjuvant analgesics will be followed, and the results of this RCT will be the first to evaluate the efficacy of pharmacological treatment on well-defined NCP.

Introduction

Management of patients with cancer experiencing opioid-refractory neuropathic pain remains an important challenge. Neuropathic pain requires multi-pharmacological therapy, with adjuvant analgesics such as anticonvulsants and antidepressants, added to opioids; however strong evidence for their efficacy in neuropathic cancer pain (NCP) is limited¹.

According to various guidelines, gabapentinoids (pregabalin, gabapentin), tricyclic antidepressants (TCA) including amitriptyline and selective serotonin noradrenalin reuptake inhibitor (SNRI) including duloxetine are recommended as first-line drugs²⁻⁵.

Among them, the effectiveness of gabapentinoids for this population has already been demonstrated in two randomised controlled trials (RCTs) compared with placebo, arguably making this a standard of care^{6,7}. Data support gabapentinoids as promising, safe agents in this setting, warranting further evaluation in robust randomised controlled trials compared with other candidates (e.g. SNRIs and TCAs). The results of two RCTs targeting NCP^{7,8}, found the effect of TCA is limited and even in small dose (e.g. amitriptyline; 30-50mg/day), many adverse events (AEs) occurred. Pregabalin was superior in terms of analgesic effect and opioid reducing effect in comparisons among

1
2
3
4
5
6 pregabalin, gabapentin, amitriptyline, and placebo⁷.

8
9 Duloxetine has been reported to be effective in the management of chemotherapy-
10 induced peripheral neuropathy (CIPN) ⁹, but no randomised trials have examined its
11 effects on opioid-refractory NCP. Although there is no standard first line treatment for
12 NCP, a systematic review and meta-analysis suggested gabapentinoids be used first ¹⁰.

13
14
15
16
17
18 Although there are few reports of duloxetine in NCP, Matsuoka et al. have conducted a
19 feasibility pre- and post-test ¹¹ and an RCT ^{12,13}, which have shown the benefit of
20 duloxetine (number needed to treat; NNT = 3.4) ¹² and superiority for tingling pain¹³.

21
22
23
24
25
26
27
28
29
30 However, there are no RCT of oral duloxetine for the management of opioid-refractory
31 NCP.

32
33
34
35
36 In the double-blind RCT described here, we will evaluate the effectiveness and harms of
37 duloxetine and pregabalin for opioid-refractory NCP. Both classes of drug have the
38 potential to reduce NCP, but there has been no head-to-head comparison for the net
39 effect especially given differing side-effect profiles. The results of this RCT will clarify
40 the first-line standard treatment for NCP.

41 42 43 44 45 46 47 48 49 50 51 52 53 54 **Methods and analysis**

55 56 57 Study design

1
2
3
4
5
6 The SPIRIT (Standard Protocol Items for Randomised Trials) statement and its
7
8
9 checklist were followed in preparing the protocol. This international, multi-centre,
10
11
12 randomised, double-blind, two-parallel arm, dose-increment study will be performed to
13
14
15 compare the efficacy and safety of duloxetine and pregabalin for NCP (Figure 1). This
16
17
18 study will also have a qualitative sub-study in which patient experience of the
19
20
21 intervention will be explored.
22

23 24 Study Settings and Participants

25
26
27 Participants will be recruited from adult palliative care sites across Japan and
28
29
30 Australia, including consultative, inpatient and community services. The inclusion and
31
32
33 exclusion criteria are summarised in Box 1.
34

35 36 Box 1. Inclusion and exclusion criteria

Inclusion Criteria
• Inpatients and outpatients with diagnoses of cancer and neuropathic pain

- 37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- An adequate opioid medication (defined as the maximum tolerated dose or titration to ≥ 60 mg/day oral morphine equivalent dose for 24 hours unless otherwise contraindicated).
- Pain related to cancer with a worst pain score of ≥ 4 or greater on BPI item 3 (worst pain intensity) score in the past 24 hours.
- Neuropathic Pain on LANSS ≥ 12 .
- Age 18 years or older (Japan 20 years or older)
- AKPS ≥ 50 .
- Taking stable regular analgesics (opioids, paracetamol, non-steroidal anti-inflammatory drugs) and any type of regular adjuvant analgesic (e.g. antidepressants, anticonvulsants, antiarrhythmic agents, N-methyl-D-aspartate receptor antagonists, and steroids) within 72 hours before commencing on the study. Short acting and rapid onset breakthrough-opioids as needed may be used ≤ 4 doses/day and still be considered "stable".

Exclusion Criteria

- Chemotherapy-Induced Peripheral Neuropathy (glove and stocking)
- Spinal cord compression
- Contraindication for duloxetine or pregabalin.
- Taking gabapentoids or duloxetine for any reason within 2 weeks.
- Taking SSRI or SNRI for any reason.
- Taking a monoamine oxidase inhibitor.
- Participants who have participated in a clinical trial involving a new chemical entity within four weeks prior to study entry.
- Starting a new chemotherapy regimen within 14 days of baseline .
- Patients with renal failure defined as eGFR $30\text{ml}/\text{min}/1.73\text{m}^2$ calculated according to the GFR-EPI equation.
- Patients with hepatic failure (Child Pugh B or C).
- Patients who have a recent history of drug abuse.
- Patients who are pregnant, breastfeeding, or may possibly be pregnant
- Other patients who are determined to be inappropriate for participation in the study by the clinical investigator

The main inclusion criterion will be adults experiencing cancer pain (neuropathic or mixed) refractory to opioids. Diagnosis of NCP is based on the International Association for the Study of Pain (IASP) criteria, in which a diagnosis of NCP is made

1
2
3
4
5
6 for patients with (1) pain with a distinct neuroanatomically plausible distribution; (2) a
7
8
9 history suggestive of a relevant lesion or disease affecting the peripheral or central
10
11
12 somatosensory system; (3) a range of pain that is neuroanatomically plausible and
13
14
15 symptoms suggesting somatosensory injury or neurological disease (i.e., hyperalgesia,
16
17
18 hypoalgesia, dysesthesia, or allodynia along the dermatome); and (4) relevant objective
19
20
21 or imaging findings suggesting nervous system injury or disease (i.e., imaging findings
22
23
24 showing that a lesion is present). Based on these criteria, the certainty of the presence of
25
26
27 NCP is graded as definite NCP (1 to 4 present) and probable NP (1 to 3) ¹⁴. Definite and
28
29
30 probable NCP will be considered to indicate NCP and patients with these conditions
31
32
33 will be eligible as subjects. Patients with a worst numerical rating scale (NRS) pain
34
35
36 score (BPI-item 3) in the preceding 24-hour period ≥ 4 ¹⁵ and those with LANSS scores
37
38
39 ≥ 12 will be included ¹⁶. The exclusion criteria will be patients with: CIPN (glove and
40
41
42 stocking); spinal cord compression; contraindications for duloxetine or pregabalin; or
43
44
45 impaired cognitive function.
46
47
48
49
50

51 Recruitment, randomisation, masking, and follow-up

54 Recruitment

57 Eligible patients satisfying the screening inclusion and exclusion criteria will be
58
59
60

1
2
3
4
5
6 invited to participate in the study by site investigators and informed consent will be
7
8
9 obtained.

10 11 12 13 14 15 Randomisation

16
17
18 Physicians will introduce the trial to patients after screening for eligibility by nurse or
19
20
21 staff. Upon enrollment, patients will be randomly allocated to duloxetine or pregabalin
22
23
24 groups in a web-based central randomisation system using minimisation methods and a
25
26
27 computer-generated randomisation schedule with a 1:1 allocation ratio. In performing
28
29
30 this allocation, we will minimise the following adjustment factors to avoid a large bias:
31
32
33 (1) worst pain intensity measured by the NRS in the last 24 h (≤ 6 , ≥ 7); (2) dose of
34
35
36 opioid (≥ 90 mg oral morphine equivalent dose, 60-90mg, < 60 mg); (3) Hospital Anxiety
37
38
39 and Depression Score (HADS) total score (≤ 10 , ≥ 11); (4) body weight (≥ 80 kg or
40
41
42 < 80 kg); (5) race (Australian (Asian descent; e.g.; China, India, Vietnam, Philippines,
43
44
45 etc.), Australian (partial or no Asian descent), Japanese, others (e.g.; Italy South, Africa,
46
47
48 etc.)), and (6) study site.
49
50
51
52
53

54 Masking

55
56
57 Patients and clinicians responsible for treatment will be blinded to administration of
58
59
60

duloxetine or pregabalin. Both the duloxetine and the pregabalin capsules will be indistinguishable by encapsulation and only unblinded pharmacists at each site will know the allocation result of each patient. Duloxetine (Cymbalta®) and pregabalin (Lyrica®) will be administered with a change in dosage form: the capsules will be covered with a No. 1 capsule (length 19mm) of the same material to make an over-capsule.

Data management, central monitoring, and audit

Evaluations will be performed at six time points: eligibility, the day before the start of treatment (day 0; the time of randomisation), day 3, day 7, day 14, and day 21 after initiation of treatment. The timing and details of evaluations are given in Table 1.

Table 1. Schedule of study measures

	Eligibility* Baseline/D1	D2	D3	D4	D5	D6	D7	D8	D 9-13	D 14	D 15-20	D 21	Exit/ WD
Investigations													
Consent Randomisation	○*												
Liver function, eGFR	○*									○			○
Study Drug Administration	○	○	○	○	○	○	○	○	○	○	○	○	○
Medical file review													
Demographics, Diagnosis	○*												

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Eligibility* Baseline/D1	D2	D3	D4	D5	D6	D7	D8	D 9-13	D 14	D 15-20	D 21	Exit/ WD
Selected medications (e.g., opioid)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Breakthrough medications	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patient assessed (PRO assessments)													
Daily Diary	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
BPI-SF	<input type="radio"/>									<input type="radio"/>			<input type="radio"/>
Worst pain (BPI-item 3)	<input type="radio"/> *	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>		<input type="radio"/>	<input type="radio"/>	
Average pain (BPI-item 5)	<input type="radio"/> *	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>		<input type="radio"/>	<input type="radio"/>	
SF-MPQ-2	<input type="radio"/>									<input type="radio"/>			<input type="radio"/>
EORTC-QLQ-PAL-C15	<input type="radio"/>									<input type="radio"/>			<input type="radio"/>
HADS	<input type="radio"/> *									<input type="radio"/>			<input type="radio"/>
Global impression of change				<input type="radio"/>				<input type="radio"/>		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>
Pain expectation	<input type="radio"/>												
PRO-AEs	<input type="radio"/>							<input type="radio"/>		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>
Clinician assessed													
Medical assessment	<input type="radio"/> *												
Height and Weight	<input type="radio"/>												
Vital signs	<input type="radio"/>									<input type="radio"/>		<input type="radio"/>	<input type="radio"/>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Eligibility* Baseline/D1	D2	D3	D4	D5	D6	D7	D8	D 9-13	D 14	D 15-20	D 21	Exit/ WD
KPS/AKPS	<input type="radio"/> *		<input type="radio"/>				<input type="radio"/>			<input type="radio"/>			<input type="radio"/>
LANSS	<input type="radio"/> *												
Personalised pain goal	<input type="radio"/>												
Adverse events	<input type="radio"/>		<input type="radio"/>				<input type="radio"/>			<input type="radio"/>	<input type="radio"/>		<input type="radio"/>
Substudies (if consented)													
Qualitative patient interview										<input type="radio"/>			

Once a patient is enrolled or randomised, the study site will make every effort to follow the patient for the entire study period. Patients will not be allowed to cross over from one group to another group until the end of the study, however, they can choose to leave the study for any reasons at any time without detriment to the provision or quality of their clinical care. The investigators at each study site will maintain individual records for each patient as source data, which will include a copy of informed consent, medical records, laboratory data and other records or notes. All data will be collected by the independent data management centre. The JORTC Data Center (Japan) and the IMPACCT Trials Coordination Centre (Australia) will oversee the intra-study data sharing process in each country. The clinical data entry, data management and central monitoring will be performed using the electric data capture VIEDOC 4 (PCG

1
2
3
4
5
6 Solutions, Sweden) in Japan and REDCap (Vanderbilt University, USA) in Australia.
7
8

9 An interim analysis will not be performed. Audit may take place by JORTC Audit
10
11

12 Committee in Japan and by an external agency in Australia.
13
14
15
16
17

18 Harms

19
20
21 Investigators must record all adverse events (AEs) in the medical records and web
22
23 systems. The National Cancer Institute's CTCAE (Ver.4.0) will be used to grade each
24
25 adverse event (AE). All AEs are to be followed up continually during their course. All
26
27 serious adverse events (SAEs) must be reported to Osaka City University Hospital
28
29 Certified Review Board (CRB) and a Medical Monitor within Australia, with annual
30
31 safety reporting to the Human Research Ethics Committee (HREC), and to investigators
32
33 in all sites. Participants that are enrolled into the study will be treated by health care
34
35 services at no cost to participants.
36
37
38
39
40
41
42
43
44
45
46
47

48 Measurement tools

49
50
51 All the appropriate permissions were obtained for the use for the assessment
52
53 instruments.
54
55
56
57
58
59
60

Brief Pain Inventory-Short Form (BPI-SF)

The Brief Pain Inventory – Short Form will be used as it is a brief and easy tool for the assessment of pain within both the clinical and research settings. It has been validated in both the chronic pain and cancer settings. The numerical rating scale of 0 to 10 is simple for participants to use and reflects common clinical assessment of pain ¹⁷.

Global Impression of Change

The Global Impression of Change is a participant-rated 7- point scale (1-7) that provides information about the participants' perception of their overall change in pain since commencing the study. This will allow the investigators to compare the pain rating using the NRS with participant perception of improvement. The results of this scale over the study period will assist to determine the clinical significance of any improvement seen ¹⁸.

Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)

The LANSS estimates the probability that neuropathic mechanisms contribute to the chronic pain experience in each participant. It has 85% sensitivity for detecting neuropathic pain. It is a seven-item scale including sensory description and

1
2
3
4
5
6 examination. A score of ≥ 12 indicates that neuropathic mechanisms are likely to
7
8
9 contribute to the participant's pain. It will be used to define a population with
10
11
12 neuropathic pain¹⁹. The LANSS will be collected to determine eligibility.
13
14
15
16
17

18 **Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2)**

19
20
21 The Short Form McGill Pain Questionnaire 2 (SF-MPQ-2)²⁰ will be used to examine
22
23 differences in effects due to pain mechanisms. The SF-MPQ-2 and its Japanese version
24
25 have been validated in cancer neuropathic pain²¹. It is a 22-item questionnaire covering
26
27 the domains of superficial and deep spontaneous pain, paroxysmal pain, evoked pain
28
29 and paresthesia/dysaesthesia. We also used this tool in the pilot study that underpins the
30
31 current trial^{12,13} and consider the possibility of effective pain types. This time it will be
32
33 used to make a comparison for that verification.
34
35
36
37
38
39
40
41
42
43
44

45 **Personalised pain goal**

46
47
48 The personalised pain goal²² is a tool used to tailor pain management to individual
49
50 needs. "Participants are asked to describe on a 0-10 scale, the level/intensity of pain that
51
52 will allow the patient to achieve comfort in physical, functional, and psychosocial
53
54 domains"²² This will be asked by the research nurse or staff at baseline, and may
55
56
57
58
59
60

1
2
3
4
5
6 include explanation of terminology. Zero will represent no pain and ten will represent
7
8
9 worst pain. This is not a validated tool. We use this scale because some argued that
10
11
12 neither between-group difference in mean values nor changes in pain intensity (e.g.
13
14
15 absolute or relative values) correctly evaluated the patient's discomfort.
16
17
18
19
20

21 **European Organization for Research and Treatment of Cancer (EORTC) QLQ-** 22 23 24 **C15-PAL**

25
26
27 The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C15-
28
29
30 PAL will be used for evaluation of patient quality of life. The reliability and validity of
31
32
33 the original version ²³ and Japanese version ²⁴ have been confirmed.
34
35
36
37
38
39

40 **Hospital Anxiety and Depression Scale (HADS)**

41
42 The Hospital Anxiety and Depression Scale (HADS) ²⁵ will be used for measurement of
43
44
45 psychiatric symptoms (anxiety and depression) of patients with a physical disease.
46
47

48
49 HADS is a screening tool that allows assessment based on a small number of items. Its
50
51
52 reliability and validity have been verified internationally ^{25, 26}.
53
54
55
56

57 **Patient Expectation**

58
59
60

1
2
3
4
5
6 Patient's expectation of a decrease in pain of each patient will be examined as one study
7
8
9 has shown the effect of expectation of pain decrease influenced pain prognosis in cancer
10
11
12 pain ²⁷.

13 14 15 16 17 18 **CTCAE/PRO-CTCAE**

19
20
21 Any new or worse adverse events will be evaluated and classified according to CTCAE
22
23
24 criteria ²⁸ and the Patient-Reported Outcomes version of the Common Terminology
25
26
27 Criteria for Adverse Events (PRO-CTCAE). PRO-CTCAE was developed by the
28
29
30 National Cancer Institute (NCI) as an adverse event assessment system to evaluate
31
32
33 patients' subjective symptoms. Its content validity and psychometric validity have been
34
35
36 verified in the original English version ^{28,29}. Japanese version of the PRO-CTCAE had
37
38
39 acceptable reliability and linguistic ³⁰ and psychometric ³¹ validity for common and
40
41
42 clinically important symptoms.
43
44
45
46
47

48 **Interventions**

49
50
51 All participants will take blinded opaque capsules each morning after breakfast and
52
53
54 bedtime for 14 days. Participants will increase the study drugs to stage 2 on day 4 and to
55
56
57 stage 3 on day 8. Participants will be assessed for AEs during the study period. If a
58
59
60

1
2
3
4
5
6 person experiences mild, moderate, or severe AEs, as classified by the NCI Criteria,
7
8
9 they will be treated symptomatically. If symptoms persist, participants will continue the
10
11
12 previous dose prior to adverse symptoms being noted (or if on the amount of stage 1
13
14
15 will exit the study). If participants experience unacceptable AEs on: days 1 - 3 on the
16
17
18 stage 1 drug (30mg duloxetine or 50mg pregabalin daily dose) they will be withdrawn
19
20
21 from the study; days 4 - 7 on the stage 2 drug (30mg duloxetine or 150mg pregabalin
22
23
24 daily dose) they will continue in the study to day 14 on stage 1 drug (30mg duloxetine
25
26
27 or 50mg pregabalin daily dose); days 8 - 14 on the stage 3 drug (60 mg duloxetine or
28
29
30 300mg pregabalin daily dose) they will continue in the study to day 14 on stage 2 drug
31
32
33 (30mg duloxetine or 150mg pregabalin daily dose) . Assessments to determine net
34
35
36 clinical effect will be conducted on day 14. The dose will be tapered down until the
37
38
39 amount of stage 1 (stage 3→2→1 or stage 2→1) and the medication will be stopped to
40
41
42 avoid a discontinuation syndrome, mirroring the schedule for initial upwards titration
43
44
45 (i.e. duloxetine 30mg/pregabalin 150 mg for 4 days, 30mg/50mg for 3 days then cease
46
47
48 <from stage 3; days 15-21> or duloxetine 30mg/pregabalin 50mg for 3 days then cease
49
50
51 < from stage 2; days 15-17 >). Rescue opioids will be available on an 'as needed' basis,
52
53
54 up to eight doses of currently prescribed breakthrough opioid in any 24-hour period.
55
56
57 Following cessation of study medications, participants will be reviewed by their treating
58
59
60

1
2
3
4
5
6 clinician regarding any future open label prescribing of the study medications. If pain is
7
8
9 present or re-occurs during the downward titration phase the treating clinician should
10
11
12 determine the most appropriate open label pain medication and monitor the patient
13
14
15 closely.
16

21 **Co-treatments**

22
23
24 Concomitantly administered analgesics such as opioids, non-steroidal anti-
25
26
27 inflammatory drugs (NSAIDs), acetaminophen, or other adjuvant analgesics such as
28
29
30 anticonvulsants, antidepressants, antiarrhythmics, N-methyl-D-aspartate (NMDA)
31
32
33 receptor antagonists, and steroids will not be changed during the follow-up period. New
34
35
36 analgesics will not be started. If nausea occurs during the treatment period, use of an
37
38
39 antiemetic will be permitted.
40
41
42
43
44

45 **Study endpoints**

48 **Primary endpoint**

49
50
51 The primary endpoint is a comparison of worst pain intensity over the previous 24
52
53
54 hours at day 14 measured using the BPI items 3 in the duloxetine and pregabalin
55
56
57 groups.
58
59
60

Secondary endpoints

Efficacy will be assessed using the following secondary endpoints: the average pain intensity (BPI items 5) at days 14 and 21; the worst pain intensity (BPI items 3) at day 21; the SF-MPQ-2 scores; EORTC QLQ-C15-PAL scores; changes in HADS score; and daily opioid dose (on each day). AEs will also be assessed using NCI CTCAE and PRO-CTCAE.

Additionally we will calculate percentage of participants with a reduction (BPI-I items 3) of 1 point; 2 point; > 2 points; 30% and 50% pain decrease from the baseline on day3, day7 and day14, percentage of participants in whom increase to the maximum dose is achieved, percentage of participants in whom can achieve personal pain goal, percentage of participants in whom need to adjust baseline opioids and adjuvant analgesics, the completion rate of the study medication and procedures, total daily dose of adjuvant analgesics use (on each day), prospectively sought adverse events with the likelihood of relationship to intervention (toxicity), and health service utilisation- planned and unplanned contact, investigations, hospitalisations.

Statistical considerations

1
2
3
4
5
6 All statistical procedures were detailed in the statistical analysis plan before data
7
8
9 evaluation, including the handling of missing values and necessity of sensitivity
10
11
12 analysis.
13
14
15
16
17

18 **Statistical hypothesis**

19
20
21 Comparison of the primary endpoint of the worst pain intensity (BPI items 3) at day
22
23
24 14 between duloxetine groups and pregabalin groups will be conducted using a two-
25
26
27 sided Student's t-test at a significance level of 5% according to the intention-to-treat
28
29
30 principle. Point estimates and 95% CIs for the difference between two group means will
31
32
33 be calculated.
34
35

36 The secondary endpoints of efficacy (BPI items 5, SF-MPQ-2, EORTC QLQ-C15-
37
38
39 PAL, HADS, daily opioid dose, and group comparison of worst pain on the BPI-item3
40
41
42 in the previous 24 hours) will be evaluated similarly to the primary endpoint.
43
44

45 Longitudinal changes in BPI-item 3 and BPI-item 5 will be evaluated using mean
46
47
48 scores and 95% CIs. The distribution of grades of adverse events (NCI CTCAE and
49
50
51 PRO-CTCAE) and the incidence of adverse events of Grade 3 or higher and of Grade 4
52
53
54 will be determined.
55
56
57
58
59
60

Sample size calculation

The difference between group BPI-item 3 on day 14 is assumed to be one point and the standard deviation of the NRS is taken to be 2.0 points^{13, 32, 33}. As there was no consensus about the minimal clinically important differences in NCP at the planning stage of the study, we decided to adopt 1-point difference compared to pregabalin as the clinical significant difference, according to the recommendation of interpreting the clinical importance of group differences in chronic pain clinical trials³².

Based on our primary outcome, which is worst pain intensity (BPI-item 3) at day 14, we will estimate 64 participants per group would detect a mean difference of 1.0 (SD 2.0; 80% power with a two-sided significance level of 0.05 for comparison).

Considering withdrawal and drop-out of 20%, we plan to recruit 160 participants into the study.

Ethical issues

All patients will be required to provide written informed consent. The study will be performed in accordance with the Declaration of Helsinki and the Japanese and Australian ethical guidelines for clinical research. The protocol was approved by the Osaka City University Hospital Certified Review Board (CRB) and a Medical Monitor

1
2
3
4
5
6 within Australia, with annual safety reporting to the Human Research Ethics Committee
7
8
9 (HREC). This trial has been registered with the clinical trials registries within both
10
11
12 Japan and Australia. Modifications in the study protocol will be communicated to
13
14
15 approving CRB (Japan) and HRECs (Australia). Each Ethics Committee or Institutional
16
17
18 Review Board will revise informed consent materials given to participants and adapt
19
20
21 according to their own institution's guidelines.
22
23
24
25
26

27 **Discussion**

28
29
30 To our knowledge, there has been no RCT of the analgesic efficacy of oral duloxetine
31
32
33 for the management of opioid refractory NCP as a first line treatment. In our planned
34
35
36 trial, the use of a randomised, double-blind, two-parallel arm design, is the most
37
38
39 appropriate design to demonstrate the efficacy of a new therapy. Our findings using this
40
41
42 approach may also allow international recommendations to be updated. We also
43
44
45 considered a crossover design, but a parallel design was finally chosen, given that the
46
47
48 crossover design has several limitations, especially in this population³⁴, namely; the
49
50
51 treatment might have carryover effects and alter the response to subsequent treatments;
52
53
54 and palliative patients may not be in a comparable condition at the start of the crossover
55
56
57 trial treatment period.
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Several issues related to the content of the trial require discussion. There will be three major concerns: (i) the heterogeneity of causes of NCP, (ii) the choice of the primary endpoint and (iii) the dose schedule of each drugs.

To address the heterogeneous causes of NCP, we excluded patients with CIPN and central NP, and targeted patients with NCP non-responsive or intolerant to opioid therapy, but the trial might still be criticised due to combination of various peripheral NCPs in one study. Narrower criteria are theoretically possible, but accrual of patients who meet these criteria is likely to be difficult. Furthermore, in palliative care field, a framework for classifying research subpopulations to which the research findings are being applied by clinicians, health planners, and funders in real-world settings has been suggested³⁵. We thus decided to include various types of peripheral NCP in the study, and sub-group analyses will be performed.

Second, the primary endpoint is the difference in worst pain intensity score at day 14 between two groups. Although we had acknowledged that the average pain intensity is adopted by many clinical trials about NCP³⁶, including three RCTs^{6,7,13} in patients with NCP, some authors recommend worst pain intensity in the last 24 hours as primary endpoints because it satisfies most key recommendations in the draft guidance¹⁵. Furthermore, to evaluate chronic pain, especially considering the nature of NCP in this

1
2
3
4
5
6 setting, we concluded that it is better to use the “worst pain intensity in the last 24
7
8
9 hours” as the primary endpoint after discussion among the members of the study’s
10
11
12 steering committee.
13
14

15 Finally, the following dose titration schedule has been devised to maximize the
16
17 likelihood of benefit while minimizing the risk of adverse events. The participant will
18
19 commence duloxetine or pregabalin at 30mg and 50mg respectively and will be titrated
20
21 according to response in increments of cessation to a maximum of 60mg (duloxetine)
22
23 and 300mg (pregabalin). Dworkin et al. conducted a systematic review of
24
25 pharmacologic management of NCP and made the recommendations for maximum
26
27 dosing ³⁷ and according to the National Comprehensive Cancer Network (NCCN)
28
29 guideline of adult cancer pain ² we have defined initiation dose and maximum dose of
30
31 both drugs.
32
33
34
35
36
37
38
39
40
41

42 Moreover, we set a dose decrement titration periods instead of doing key open to
43
44 avoid a discontinuation syndrome of each drug and to keep scientific reliability.
45
46
47

48 Therefore, the planned international double-blind multi-centre RCT will be the first to
49
50 evaluate the efficacy and harms of duloxetine and pregabalin treatment in patients
51
52 suffering from well-defined NCP refractory to opioids, and the results of the trial will
53
54 clarify the first-line standard treatment for NCP.
55
56
57
58
59
60

Trial status

The trial opened in January 2020. At the time of manuscript submission (February 2021), twenty one patients have been randomised. We expect to complete the recruitment by September 2022 and to finish this trial by March 2023.

Confidentially

Data will be retained in accordance with the Japanese Clinical Research Act and the Australian regulations for Good Clinical Practice. Participants will be allocated a unique identification (ID) number at entry. The master list linking participant personal information and ID number will be maintained in a separate locked cabinet and password-protected hard drive at each institution. Data will be analysed by ID number only. Records will be retained for 15 years after study completion and then destroyed by the data centre.

Dissemination

The results of this trial will be submitted for publication in international peer-reviewed journals and the key findings presented at conferences. Participants will be informed of

1
2
3
4
5
6 the results of the trial by the investigators. Authorship will be ascribed in accordance
7
8
9 with the International Committee of Medical Journal Editors guidance.
10
11
12
13
14

15 **Data Sharing Statement**

16
17
18 Immediately after the publication of the primary results, de-identified individual
19
20
21 participant data that underlie the results reported in the article(s) and other documents
22
23
24 (study protocol and statistical analysis plan) will be available for any purpose, only if
25
26
27 approved by JORTC Independent Data Monitoring Committee (IDMC) and the CST
28
29
30 Scientific Advisory Committee.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Access to data**

52
53
54 JORTC Data Center and JORTC Independent Data Monitoring Committee have access
55
56
57 to the final trial dataset. There is no contractual agreement regarding investigators'
58
59
60 access restrictions on dataset.

51 **Declarations**

52
53
54 The protocol was approved by the Osaka City University Hospital Certified Review
55
56
57 Board and South Western Sydney Local Health District Human Research Ethics
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Committee (Australia). Informed consent for participation in the trial will be obtained from all patients.

Patient and Public Involvement

The invaluable contribution of healthcare consumers (patients and caregivers) is recognised by ensuring that all research undertaken takes into account consumer experience and perspectives. Consumer representatives were actively involved in all aspects of our research including the design, implementation, evaluation, and dissemination of this randomised control clinical trial. As a member of the protocol investigator team, the consumer representative ensures that the physical and emotional wellbeing of patients and caregivers were taken into consideration when planning this clinical trial and implementing the result findings into practice.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the following grant: 2017-2019 Japan Agency for Medical

1
2
3
4
5
6 Research and Development (AMED) award (19ck0106328h0003, Innovative Clinical
7
8
9 Cancer Research) and will be supported by the following grants: 2020-2024 Australian
10
11
12 Government National Health and Medical Research Council Clinical Trials and Cohort
13
14
15 Studies funding (NHMRC: APP1188023) and 2020-2022 Japan Agency for Medical
16
17
18 Research and Development (AMED) award (20ck0106603h9901, Innovative Clinical
19
20
21 Cancer Research). The entire research organization has no conflicts of interest to
22
23
24 declare.
25
26
27
28
29

30 **Sponsor detail**

31
32
33 Division of Cancer Research Department of Research Promotion

34
35
36 Japan Agency for Medical Research and Development

37
38
39 22F Yomiuri Shimbun Bldg. 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

40
41
42 Phone: +81-3-6870-2221

43
44
45 Fax: +81-3-6870-2244
46
47
48
49

50
51 University of Technology Sydney (UTS)

52
53
54 Cancer Symptom Trials (CST), IMPACCT

55
56
57 Broadway, ULTIMO, NSW 2007, Australia
58
59
60

1
2
3
4
5
6 Phone: +61 2 9514 2000
7
8

9 CST@uts.edu.au
10
11
12
13
14

15 Abbreviations 16

17
18 NP: Neuropathic pain; NCP: Neuropathic cancer pain; TCA: Tricyclic
19
20 Antidepressant; SNRI: Serotonin & Norepinephrine Reuptake Inhibitors; IASP:
21
22 International Association for the Study of Pain; BPI: Brief pain inventory; LANSS: the
23
24 Leeds assessment of neuropathic symptoms and signs; CIPN: Chemotherapy-Induced
25
26 Peripheral Neuropathy; NRS: Numerical Rating Scale; HADS: Hospital Anxiety and
27
28 Depression Scale; AE: Adverse event; CTCAE: Common Terminology Criteria for
29
30 Adverse Events; SF-MPQ: Short-Form McGill Pain Questionnaire; EORTC: European
31
32 Organization for Research and Treatment; NSAIDs: Non-Steroidal Anti-Inflammatory
33
34 Drugs; NMDA: N-methyl-D-aspartate; JORTC: Japanese Organization for Research
35
36 and Treatment of Cancer
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Authors' contributions 52

53
54 HM, KC, BF, LB, HI, YM, HH, KA, JL, BL, PA, SK, NF, TM, ML, MA, ES, SI, JP,
55
56
57 AK, and DC participated in the design of the study. SO, TY, designed the statistical
58
59
60

1
2
3
4
5
6 analysis plan. All authors contributed to writing and revising the manuscript critically,
7
8
9 and all gave their final approval of the version to be published.
10
11
12
13
14

15 Acknowledgements

16
17
18 We are grateful for support from the Japan Agency for Medical Research and
19
20
21 Development (AMED), Grant-in-Aid for Scientific Research, and the Australian
22
23
24 Government National Health and Medical Research Council (NHMRC) Clinical Trials
25
26
27 and Cohort Studies funding. The authors thank in advance all the patients, investigators,
28
29
30 consumer representatives and institutions involved in this study.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Jongen JL, Huijsman ML, Jessurun J, et al. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. *Journal of pain and symptom management*. 2013;46(4):581-90.e1.
2. Swarm RA, Dans M: NCCN Frameworks for Resource Stratification of NCCN Guidelines: Adult Cancer Pain and Palliative Care. *J Natl Compr Canc Netw* 16:628-631, 2018
3. Piano V, Verhagen S, Schalkwijk A, et al. Treatment for neuropathic pain in patients with cancer: comparative analysis of recommendations in national clinical practice guidelines from European countries. *Pain Pract*. 2014 Jan;14(1):1-7. doi: 10.1111/papr.12036.
4. Piano V, Schalkwijk A, Burgers J, et al. Guidelines for neuropathic pain management in patients with cancer: a European survey and comparison. *Pain Pract*. 2013 Jun;13(5):349-57. doi: 10.1111/j.1533-2500.2012.00602.x.
5. Attal N, Cruccu G, Baron R, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol*. 2010 Sep;17(9):1113-e88. doi: 10.1111/j.1468-1331.2010.02999.x.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2004;22(14):2909-17.
7. Mishra S, Bhatnagar S, Goyal GN, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. *Am J Hosp Palliat Care*. 2012;29:177-82.
8. Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. *Tumori*. 2002;88(3):239-42.
9. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. *JAMA*. 2013;309:1359-67.
10. Kane CM, Mulvey MR, Wright S, et al. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. *Palliat Med*. 2018;32:276-286.

- 1
2
3
4
5
6
7 11. Matsuoka H, Makimura C, Koyama A, et al. Pilot study of duloxetine for cancer
8
9 patients with neuropathic pain non-responsive to pregabalin. *Anticancer Res.*
10
11 2012;32:1805-10.
12
13
14
15 12. Matsuoka H, Iwase S, Miyaji T, et al. Predictors of duloxetine response in patients
16
17 with neuropathic cancer pain: a secondary analysis of a randomized controlled
18
19 trial—JORTC-PAL08 (DIRECT) study. *Supportive Care in Cancer.* 2020
20
21 Jun;28(6):2931-2939. doi: 10.1007/s00520-019-05138-9.
22
23
24
25
26
27 13. Matsuoka H, Iwase S, Miyaji T, et al. Additive Duloxetine for Cancer-Related
28
29 Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A
30
31 Randomized Controlled Trial (JORTC-PAL08). *J Pain Symptom Manage.* 2019 Jun
32
33 26. pii: S0885-3924(19)30364-1. doi: 10.1016/j.jpainsymman.2019.06.020.
34
35
36
37
38
39 14. Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated
40
41 grading system for research and clinical practice. *Pain.* 2016;157:1599-606.
42
43
44
45 15. Atkinson TM, Mendoza TR, Sit L, et al. The brief pain inventory and its "pain at its
46
47 worst in the last 24 hours" item: clinical trial endpoint considerations. *Pain Med*
48
49 2010;11:337-46.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 16. Mulvey MR, Boland EG, Bouhassira D, et al. Neuropathic pain in cancer:
8
9 systematic review, performance of screening tools and analysis of symptom profiles.
10
11
12 Br J Anaesth. 2017 ;119(4):765-774. doi: 10.1093/bja/aex175.
13
14
- 15 17. Cleeland CS. Measurement of pain by subjective report. In: Chapman CRL, J.D.,
16
17 editor. *Advances in Pain Research and Therapy. Volume 12: Issues in Pain*
18
19 *Measurement*. New York: Raven Press; 1989. p. 391-403.
20
21
22
- 23 18. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. Clinical importance
24
25 of changes in chronic pain intensity measured on an 11-point numerical pain rating
26
27 scale. *Pain*. 2001;94(2):149-58.
28
29
30
31
- 32 19. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms
33
34 and signs. *Pain*. 2001;92(1-2):147-57.
35
36
37
38
- 39 20. Dworkin RH, Turk DC, Revicki DA, et al: Development and initial validation of an
40
41 expanded and revised version of the Short-form McGill Pain Questionnaire (SF-
42
43 MPQ-2). *Pain* 144:35-42, 2009
44
45
46
47
- 48 21. Maruo T, Nakae A, Maeda L, et al. Validity, reliability, and assessment sensitivity
49
50 of the Japanese version of the short-form McGill pain questionnaire 2 in Japanese
51
52 patients with neuropathic and non-neuropathic pain. *Pain Med* 2014;15:1930-7.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 22. Dalal S, Hui D, Nguyen L, et al. Achievement of personalized pain goal in cancer
8
9 patients referred to a supportive care clinic at a comprehensive cancer center.
10
11
12 Cancer. 2012;118(15):3869-77.
13
14
- 15 23. Groenvold M, Petersen MA, Aaronson NK, et al: The development of the EORTC
16
17
18 QLQ-C15-PAL; a shortened questionnaire for cancer patients in palliative care. Eur
19
20
21 J Cancer 42: 55-64, 2006
22
23
- 24 24. Miyazaki K, Suzukamo Y, Shimosuma K, et al: Verification of the psychometric
25
26
27 properties of the Japanese version of the European Organization for Research and
28
29
30 Treatment of Cancer Quality of Life Questionnaire Core 15 palliative
31
32
33 (EORTCQLQ-C15-PAL). Qual Life Res 21: 335-340, 2012.
34
35
- 36 25. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr
37
38
39 Scand 1983;67:361-70.
40
41
- 42 26. Kugaya A, Akechi T, Okuyama T, et al. Screening for psychological distress in
43
44
45 Japanese cancer patients. Jpn J Clin Oncol 1998;28:333-8.
46
47
- 48 27. Matsuoka H, Yoshiuchi K, Koyama A, et al. Expectation of a Decrease in Pain
49
50
51 Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of
52
53
54 Response to Morphine. Int J Behav Med. 2017 Aug;24(4):535-541. doi:
55
56
57 10.1007/s12529-017-9644-5.
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. Hay JL, Atkinson TM, Reeve BB, et al. NCI PRO-CTCAE Study Group. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Qual Life Res* 2014 Feb;23(1):257-69. doi: 10.1007/s11136-013-0470-1.
29. Dueck AC, Mendoza TR, Mitchell SA, et al. National Cancer Institute PRO-CTCAE Study Group. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *JAMA Oncol* 2015 Nov;1(8):1051-9. Erratum in: *JAMA Oncol*. 2016 Jan;2(1):146.
30. Miyaji T, Iioka Y, Kuroda Y, et al.: Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *J Patient Rep Outcomes*. 2017;1(1):8. doi: 10.1186/s41687-017-0012-7.
31. Kawaguchi T, Azuma K, Sano M, et al: The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events. *J Patient Rep Outcomes*. 2017;2(1):2. doi: 10.1186/s41687-017-0022-5.

- 1
2
3
4
5
6
7 32. Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance
8
9 of group differences in chronic pain clinical trials: IMMPACT recommendations.
10
11
12 Pain. 2009 Dec;146(3):238-44. doi: 10.1016/j.pain.2009.08.019.
13
14
- 15 33. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain
16
17 in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015;14:162–
18
19 73.doi:10.1016/S1474-4422(14)70251-0.
20
21
22
- 23 34. Senn SS. *Cross-over trials in clinical research*. Chichester: John Wiley & Sons,
24
25 2002.
26
27
- 28 35. Currow DC, Wheeler JL, Glare PA, Kaasa S, Abernethy AP. A framework for
29
30 generalizability in palliative care. *J Pain Symptom Manage* 2009;37:373e386.
31
32
33
- 34 36. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. *Cochrane*
35
36
37 *Database Syst Rev* 2013;29:8 CD006146.
38
39
- 40 37. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of
41
42
43 neuropathic pain: Evidence-based recommendations. *Pain*. 2007;132:237-51.
44
45
46
47
48
49
50

51 **Figure Legends**

52
53
54 Figure 1. Flow chart of the procedures in the study. Participants will be randomized (1:1
55
56 allocation ratio) into the duloxetine group or the pregabalin group.
57
58
59
60




Fig.1. Flow chart of the procedures in the study



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	※ 1
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	25
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	27
	5b	Name and contact information for the trial sponsor	25-26
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Not applicable
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	※ 1
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5-6
	6b	Explanation for choice of comparators	5-6
Objectives	7	Specific objectives or hypotheses	6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7, Box1
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	15-16
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	15-16
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	12-13
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	16
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	17
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6, Table1, Figure1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	19-20
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9
---------------------	-----	--	---

1	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	9
2	concealme		telephone; sequentially numbered, opaque, sealed envelopes),	
3	nt		describing any steps to conceal the sequence until interventions are	
4	mechanis		assigned	
5	m			
6				
7	Implement	16c	Who will generate the allocation sequence, who will enrol participants,	9
8	ation		and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	9
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13				
14				
15		17b	If blinded, circumstances under which unblinding is permissible, and	9
16			procedure for revealing a participant's allocated intervention during the	
17			trial	
18				
19				
20				
21	Methods: Data collection, management, and analysis			
22	Data	18a	Plans for assessment and collection of outcome, baseline, and other	9-10
23	collection		trial data, including any related processes to promote data quality (eg,	
24	methods		duplicate measurements, training of assessors) and a description of	
25			study instruments (eg, questionnaires, laboratory tests) along with their	
26			reliability and validity, if known. Reference to where data collection	
27			forms can be found, if not in the protocol	
28				
29				
30		18b	Plans to promote participant retention and complete follow-up, including	16
31			list of any outcome data to be collected for participants who discontinue	
32			or deviate from intervention protocols	
33				
34				
35	Data	19	Plans for data entry, coding, security, and storage, including any related	※
36	management		processes to promote data quality (eg, double data entry; range checks	2
37			for data values). Reference to where details of data management	
38			procedures can be found, if not in the protocol	
39				
40				
41	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	18
42	methods		Reference to where other details of the statistical analysis plan can be	
43			found, if not in the protocol	
44				
45		20b	Methods for any additional analyses (eg, subgroup and adjusted	18
46			analyses)	
47				
48				
49		20c	Definition of analysis population relating to protocol non-adherence (eg,	※
50			as randomised analysis), and any statistical methods to handle missing	3
51			data (eg, multiple imputation)	
52				
53				
54	Methods: Monitoring			
55	Data	21a	Composition of data monitoring committee (DMC); summary of its role	※ 1
56	monitoring		and reporting structure; statement of whether it is independent from the	
57			sponsor and competing interests; and reference to where further details	
58			about its charter can be found, if not in the protocol. Alternatively, an	
59			explanation of why a DMC is not needed	
60				

1		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	10
2				
3				
4				
5	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
6				
7				
8				
9	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	10
10				
11				
12				
13	Ethics and dissemination			
14				
15	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	20
16				
17				
18				
19	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	20
20				
21				
22				
23				
24				
25	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8,10
26				
27				
28				
29		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	Not applicable
30				
31				
32	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	23-24
33				
34				
35				
36	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	25
37				
38				
39	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	24
40				
41				
42				
43				
44	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	16
45				
46				
47	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	✖ 4
48				
49				
50				
51				
52				
53		31b	Authorship eligibility guidelines and any intended use of professional writers	24
54				
55				
56		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	Not planned
57				
58				
59				
60	Appendices			

1	Informed	32	Model consent form and other related documentation given to	20
2	consent		participants and authorised surrogates	
3	materials			
4				
5	Biological	33	Plans for collection, laboratory evaluation, and storage of biological	Not
6	specimens		specimens for genetic or molecular analysis in the current trial and for	applicable
7			future use in ancillary studies, if applicable	
8				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

※ 1 : Not stated in the protocol paper due to word limits.

※ 2 : There is a statement in the data management plan, however not stated in the protocol paper due to word limits.

※ 3 : There is a statement in the statistical analyses plan (definition of analysis population relating to protocol non-adherence, and any statistical methods to handle missing data) however not stated in the protocol paper due to word limits.

※ 4 : There is a statement in the Informed consent form, however, not stated in the protocol paper due to word limits.

BMJ Open

Phase III, international, multi-centre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: A JORTC-PAL16 Trial Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050182.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Oct-2021
Complete List of Authors:	<p>Matsuoka, Hiromichi; National Cancer Center Japan, Clark, Katherine; University of Technology Sydney, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation)</p> <p>Fazekas, Belinda; University of Technology Sydney, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation)</p> <p>Oyamada, Shunsuke; Japanese Organisation for Research and Treatment of Cancer, Biostatistics</p> <p>Brown, Linda; University of Technology Sydney, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation)</p> <p>Ishiki, Hiroto; National Cancer Center Japan, Matsuda, Yoshinobu; National Hospital Organization Kinki-Chuo Chest Medical Center,</p> <p>Hasuo, Hideaki; Kansai Medical University Hirakata Hospital, Psychosomatic medicine</p> <p>Ariyoshi, Keisuke; Institute of Medical Science, The University of Tokyo, Palliative Medicine</p> <p>Lee, Jessica; University of Technology Sydney, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation)</p> <p>Le, Brian; Royal Melbourne Hospital</p> <p>Allcroft, Peter; University of Technology Sydney, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation)</p> <p>Kochovska, Slavica; University of Technology Sydney Faculty of Health, IMPACCT (Improving Palliative, Aged and Chronic Care through Clinical Research and Translation)</p> <p>Fujiwara, Noriko; The Institute of Medical Science, The University of Tokyo</p> <p>Miyaji, Tempei; University of Tokyo, Department of Clinical Trial Data Management, Graduate School of Medicine</p> <p>Lovell, Melanie; Greenwich Hospital, Palliative Care</p> <p>Agar, Meera ; University of Technology Sydney, Centre of Cardiovascular and Chronic Care, Faculty of Health</p> <p>Yamaguchi, Takuhiro; Division of Biostatistics, Satomi, Eriko; National Cancer Center Japan Chuo-ku</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Iwase, Satoru; Institute of Medical Science, The University of Tokyo,, Department of Palliative Medicine Phillips, Jane; University of Technology Sydney, Faculty of Health Koyama, Atsuko; Kindai University Faculty of Medicine, Currow, David ; University of Technology Sydney, ; Cancer Institute New South Wales,
Primary Subject Heading:	Palliative care
Secondary Subject Heading:	Palliative care
Keywords:	Adult palliative care < PALLIATIVE CARE, Cancer pain < ONCOLOGY, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

STUDY PROTOCOL

Phase III, international, multi-centre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: A JORTC-PAL16 Trial Protocol

Matsuoka H ^{1,2}, Clark K ², Fazekas B ², Oyamada S ³, Brown L ², Ishiki H ¹, Matsuda Y ⁴, Hasuo H ⁵, Ariyoshi K ³, Lee J ^{2,6}, Le B ², Allcroft P ², Kochovska S ², Fujiwara N ⁷, Miyaji T ⁸, Lovell MR ^{2,9}, Agar M ², Yamaguchi T ¹⁰, Satomi E ¹, Iwase S ¹¹, Phillips J ², Koyama A ¹², Currow DC ²

1. National Cancer Centre Hospital, Tokyo, Japan
2. IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia
3. Japanese Organisation for Research and Treatment of Cancer (JORTC), NPO, Tokyo, Japan
4. Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan
5. Palliative Care Centre, Kansai Medical University, Osaka, Japan
6. Concord Centre for Palliative Care, Concord Hospital, Sydney, NSW, Australia
7. The Institute of Medical Science, The University of Tokyo
8. Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
9. HammondCare, Greenwich Hospital, Greenwich NSW Australia

1
2
3
4
5
6 10. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai,
7

8 Japan
9

10 11. Department of Palliative Medicine, Saitama Medical University hospital, Saitama,
11

12 Japan
13

14 12. Department of Psychosomatic Medicine, Kindai University Faculty of Medicine,
15

16 Osaka, Japan
17
18
19
20
21

22 Corresponding Author: Hiromichi Matsuoka
23

24 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
25

26 Tel.: +81-3-3547-5248
27

28 E-mail:hiromima@ncc.go.jp
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Management of neuropathic cancer pain (NCP) refractory to regular opioids remains an important challenge. The efficacy of pregabalin for NCP except chemotherapy-induced peripheral neuropathy (CIPN) has already been confirmed in two randomised controlled trials (RCTs) compared with placebo. Duloxetine offers the potential of analgesia in opioid refractory NCP. However, there are no RCT of duloxetine for the management of opioid-refractory NCP as a first line treatment. Both classes of drugs have the potential to reduce NCP, but there has been no head-to-head comparison for the efficacy and safety, especially given differing side-effect profiles.

Methods and analysis: An international, multi-centre, double-blind, dose increment, parallel-arm, RCT is planned. Inclusion criteria include: adults with cancer experiencing NCP refractory to opioids; Brief Pain Inventory (BPI)-item 3 (worst pain) of ≥ 4 ; Neuropathic Pain on the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (LANSS) of ≥ 12 despite of an adequate trial of regular opioid medication (≥ 60 mg/day oral morphine equivalent dose). Patients with CIPN are excluded.

The study will recruit from palliative care teams (both inpatients and outpatients) in Japan and Australia. Participants will be randomised (1:1 allocation ratio) to duloxetine or pregabalin arm. Dose escalation is until day 14 and from day 14 to 21 is a dose de-

1
2
3
4
5
6 escalation period to avoid withdrawal effects. The primary endpoint is defined as the
7
8
9 mean difference in BPI item 3 for worst pain intensity over the previous 24 hours at day
10
11
12 14 between groups. A sample size of 160 patients will be enrolled between February
13
14
15 2020 and March 2023.

16
17
18 **Ethics and Dissemination:** Ethics approval was obtained at Osaka City University
19
20
21 Hospital Certified Review Board and South Western Sydney Local Health District
22
23
24 Human Research Ethics Committee. The results of this study will be submitted for
25
26
27 publication in international journals and the key findings presented at international
28
29
30 conferences.
31

32
33
34
35
36 Trial registration number: jRCTs051190097, Date of registration: 27 January 2020.

37
38
39 ACTRN12620000656932, Date of registration: 5 June 2020.
40
41
42
43
44

45 **Keywords:** duloxetine, pregabalin, randomised controlled trial, neuropathic cancer
46
47
48 pain, palliative care.
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitation of this study

- This is the first study to compare the analgesic efficacy and safety of duloxetine with pregabalin in patients experiencing neuropathic cancer pain refractory to opioids, not induced by chemotherapy. The results of the trial will clarify the first-line standard of care for neuropathic cancer pain.
- A high-quality double blind multicentre RCT study design adequately powered to provide a clinically meaningful outcome, and enable the safety and tolerability following intervention to be prospectively and systematically evaluated.
- This study includes heterogenous causes of neuropathic cancer pain not related to chemotherapy to determine the pharmacological effects of pregabalin and duloxetine in sparsely studied but clinically relevant populations.
- The primary endpoint is not average pain intensity over the past 24 hours but the difference in worst pain intensity score, which has shown the highest degree of internal consistency for assessing a pain-reduction treatment effect.
- Recommendations for maximum dosing of adjuvant analgesics will be followed, and the results of this RCT will be the first to evaluate the efficacy of pharmacological treatment on well-defined NCP.

Introduction

Management of patients with cancer experiencing opioid-refractory neuropathic pain remains an important challenge. Neuropathic pain requires multi-pharmacological therapy, with adjuvant analgesics such as anticonvulsants and antidepressants, added to opioids; however strong evidence for their efficacy in neuropathic cancer pain (NCP) is limited¹.

According to numerous guidelines, gabapentinoids (pregabalin, gabapentin), tricyclic antidepressants (TCA) including amitriptyline and selective serotonin noradrenalin reuptake inhibitor (SNRI) including duloxetine are recommended with careful titration as first-line drugs²⁻⁷. Among them, the efficacy of gabapentinoids for this population has already been demonstrated in three randomised controlled trials (RCTs) compared with placebo, arguably making this a standard of care⁸⁻¹⁰. Data support gabapentinoids as promising, safe agents in this setting, warranting further evaluation in robust randomised controlled trials compared with other candidates (e.g., SNRIs and TCAs).

The results of two RCTs targeting NCP^{10,11}, found the effect of TCA is limited and even in small dose (e.g., amitriptyline; 30-50mg/day), many adverse events (AEs) occurred. Pregabalin was superior in terms of analgesic effect and opioid reducing effect in comparisons among pregabalin, gabapentin, amitriptyline, and placebo¹⁰.

1
2
3
4
5
6 Duloxetine has been reported to be effective in the management of chemotherapy-
7
8
9 induced peripheral neuropathy (CIPN) ¹², but no randomised trials have examined its
10
11
12 effects on opioid-refractory NCP. Although there is no standard first line treatment for
13
14
15 NCP, a systematic review and meta-analysis suggested gabapentinoids be used first ¹³.
16
17
18 Although there are few reports of duloxetine in NCP, Matsuoka et al. have conducted a
19
20
21 feasibility pre- and post-test ¹⁴ and an RCT ^{15,16}, which have shown the benefit of
22
23
24 duloxetine (number needed to treat; NNT = 3.4) ¹⁵ and superiority for tingling pain¹⁶.
25
26
27 However, there are no RCT of oral duloxetine for the management of opioid-refractory
28
29
30 NCP.
31

32
33 In the double-blind RCT described here, we will evaluate the efficacy and safety of
34
35
36 duloxetine and pregabalin for opioid-refractory NCP. Both classes of drug have the
37
38
39 potential to reduce NCP, but there has been no head-to-head comparison for the efficacy
40
41
42 and safety especially given differing side-effect profiles. The results of this RCT may
43
44
45 help to clarify the first-line standard treatment for NCP.
46
47
48
49
50

51 **Methods and analysis**

52 Study design

53
54
55
56
57 The SPIRIT (Standard Protocol Items for Randomised Trials) statement and its
58
59
60

1
2
3
4
5
6 checklist were followed in preparing the protocol. This international, multi-centre,
7
8
9 randomised, double-blind, two-parallel arm, dose-increment study will be performed to
10
11
12 compare the efficacy and safety of duloxetine and pregabalin for NCP (Figure 1). This
13
14
15 study will also have a qualitative sub-study in which patient experience of the
16
17
18 intervention will be explored if additional consent is provided.
19

20 21 Study Settings and Participants

22
23
24 Participants will be recruited from adult palliative care sites across Japan and
25
26
27 Australia (both inpatients and outpatients). The inclusion and exclusion criteria are
28
29
30 summarised in Box 1.
31

32 33 34 35 36 Box 1. Inclusion and exclusion criteria

37 Inclusion Criteria

- 38
39
40 • Inpatients and outpatients with diagnoses of cancer and neuropathic pain who, in the
41 opinion of the site investigator, are candidates for therapy with duloxetine or pregabalin
42
43
- 44
45 • Insufficient response (defined as pain related to cancer with a worst pain score of ≥ 4 or
46 greater on BPI item 3 (worst pain intensity) score in the past 24 hours) to an adequate
47 opioid medication (defined as the maximum tolerated dose or titration to at least 60mg/day
48 oral morphine equivalent dose for 24 hours unless contra-indicated or further escalation
49 is deemed unnecessary or inappropriate in the opinion of the clinical investigator).
50
- 51 • Age 18 years or older (Japan 20 years or older)
- 52 • AKPS ≥ 50 .
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
- Taking stable regular analgesics (opioids, paracetamol, non-steroidal anti-inflammatory drugs) and any type of regular adjuvant analgesic (e.g. antidepressants, anticonvulsants, antiarrhythmic agents, N-methyl-D-aspartate receptor antagonists, and steroids) within 72 hours before commencing on the study. Short acting and rapid onset breakthrough-opioids as needed may be used ≤ 4 doses/day and still be considered "stable".

Exclusion Criteria

- 15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
- Chemotherapy-Induced Peripheral Neuropathy (glove and stocking distribution and prior use of a therapy known to cause this)
 - Spinal cord compression
 - Contraindication for duloxetine or pregabalin.
 - Taking gabapentoids or duloxetine for any reason within the previous two weeks.
 - Taking SSRI or SNRI for any reason.
 - Taking a monoamine oxidase inhibitor.
 - Participants who have participated in a clinical trial involving a new chemical entity within four weeks prior to study entry.
 - Starting a new chemotherapy regimen within 14 days of baseline.
 - Patients with renal failure defined as eGFR ≤ 30 ml/min/1.73m² calculated according to the GFR-EPI equation.
 - Patients with hepatic failure (Child Pugh B or C).
 - Patients who have a recent history of drug misuse.
 - Patients who are pregnant, breastfeeding, or may possibly be pregnant
 - Other patients who are determined to be inappropriate for participation in the study by the clinical investigator
-

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The main inclusion criterion will be adults experiencing cancer pain (neuropathic or mixed) refractory to opioids. Diagnosis of NCP is based on the International Association for the Study of Pain (IASP) criteria, in which a diagnosis of NCP is made for patients with (1) pain with a distinct neuroanatomically plausible distribution; (2) a history suggestive of a relevant lesion or disease affecting the peripheral or central

1
2
3
4
5
6 somatosensory system; (3) a range of pain that is neuroanatomically plausible and
7
8
9 symptoms suggesting somatosensory injury or neurological disease (i.e., hyperalgesia,
10
11
12 hypoalgesia, dysesthesia, or allodynia along the dermatome); and (4) relevant objective
13
14
15 or imaging findings suggesting nervous system injury or disease (i.e., imaging findings
16
17
18 showing that a lesion is present). Based on these criteria, the certainty of the presence of
19
20
21 NCP is graded as definite NCP (1 to 4 present) and probable NP (1 to 3) ¹⁷. Definite and
22
23
24 probable NCP will be considered to indicate NCP and patients with these conditions
25
26
27 will be eligible as subjects. Patients with a worst numerical rating scale (NRS) pain
28
29
30 score (BPI-item 3) in the preceding 24-hour period ≥ 4 ¹⁸ and those with LANSS scores
31
32
33 ≥ 12 will be included ¹⁹. The exclusion criteria will be patients with: CIPN (glove and
34
35
36 stocking); spinal cord compression; contraindications for duloxetine or pregabalin; or
37
38
39 impaired cognitive function.
40
41
42
43
44

45 Recruitment, randomisation, masking, and follow-up

47 48 Recruitment

49
50
51 Eligible patients satisfying the screening inclusion and exclusion criteria will be
52
53
54 invited to participate in the study by site investigators and informed consent will be
55
56
57 obtained.
58
59
60

Randomisation

Physicians will introduce the trial to patients after screening for eligibility by nurse or staff. Upon enrollment, patients will be randomly allocated to duloxetine or pregabalin groups in a web-based central randomisation system using minimisation methods and a computer-generated randomisation schedule with a 1:1 allocation ratio. In performing this allocation, we will minimise the following adjustment factors²⁰ to avoid a large bias: (1) worst pain intensity measured by the NRS in the last 24 h ($\leq 6, \geq 7$)^{2,21}; (2) dose of opioid (≥ 90 mg oral morphine equivalent dose, 60-90mg, < 60 mg)^{22,23}; (3) Hospital Anxiety and Depression Score (HADS) total score ($\leq 10, \geq 11$)²⁴; (4) body weight (≥ 80 kg or < 80 kg)²⁵; (5) race (Australian (Asian descent; e.g.; China, India, Vietnam, Philippines, etc.)²⁵, Australian (partial or no Asian descent), Japanese, others (e.g.; Italy South, Africa, etc.)), and (6) study site^{25,26}.

Masking

Patients and clinicians responsible for treatment will be blinded to administration of duloxetine or pregabalin. Both the duloxetine and the pregabalin capsules will be indistinguishable by encapsulation and only unblinded pharmacists at each site will

know the allocation result of each patient. Duloxetine (Cymbalta®) and pregabalin (Lyrica®) will be administered with a change in dosage form: the capsules will be covered with a No. 1 capsule (length 19mm) of the same material to make an over-capsule.

Data management, central monitoring, and audit

Evaluations will be performed at eight time points: eligibility, the day before the start of treatment (day 0; the time of randomisation), day 3, day 4, day 7, day 8, day 14, and day 21 after initiation of treatment. The timing and details of evaluations are given in

Table 1.

Table 1. Times and Events Schedule

	Eligibility* Baseline/D1	D2	D3	D4	D5	D6	D7	D8	D 9-13	D 14/ET	D 15-20	D 21 (EOS)
Investigations												
Consent Randomisation	○*											
Liver function, eGFR	○*									○		
Study Drug Administration	○	○	○	○	○	○	○	○	○	○	○	○
Medical file review												
Demographics, Diagnosis	○*											

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Eligibility* Baseline/D1	D2	D3	D4	D5	D6	D7	D8	D 9-13	D 14/ET	D 15-20	D 21 (EOS)
Selected medications (e.g., opioid)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Breakthrough medications	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patient assessed (PRO assessments)												
Daily Diary	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
BPI-SF	<input type="radio"/>									<input type="radio"/>		
Worst pain (BPI-item 3)	<input type="radio"/> *	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>		<input type="radio"/>	<input type="radio"/>
Average pain (BPI-item 5)	<input type="radio"/> *	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>		<input type="radio"/>	<input type="radio"/>
SF-MPQ-2	<input type="radio"/>									<input type="radio"/>		
EORTC-QLQ-PAL-C15	<input type="radio"/>									<input type="radio"/>		
HADS	<input type="radio"/> *									<input type="radio"/>		
Global impression of change				<input type="radio"/>				<input type="radio"/>		<input type="radio"/>		<input type="radio"/>
Pain expectation	<input type="radio"/>											
PRO-CTCAE	<input type="radio"/>							<input type="radio"/>		<input type="radio"/>		<input type="radio"/>
Clinician assessed												
Medical assessment	<input type="radio"/> *											
Height and Weight	<input type="radio"/>											
Vital signs	<input type="radio"/>									<input type="radio"/>		<input type="radio"/>

	Eligibility* Baseline/D1	D2	D3	D4	D5	D6	D7	D8	D 9-13	D 14/ET	D 15-20	D 21 (EOS)
AKPS	<input type="radio"/> *		<input type="radio"/>				<input type="radio"/>			<input type="radio"/>		
LANSS	<input type="radio"/> *											
Personalised pain goal	<input type="radio"/>											
Adverse events (CTCAE)	<input type="radio"/>		<input type="radio"/>				<input type="radio"/>			<input type="radio"/>		<input type="radio"/>
Substudies (if consented)												
Qualitative patient interview										<input type="radio"/>		

BPI-SF: Brief Pain Inventory-Short Form, SF-MPQ2: Short-Form McGill Pain Questionnaire-2, EORTC-QLQ-PAL-C15: The European Organisation for Research and Treatment of Cancer quality of life core 15 palliative questionnaire, HADS: Hospital Anxiety and Depression Scale, PRO-CTCAE: Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, AKPS: Australia-modified Karnofsky Performance Status, LANSS: the Leeds Assessment of Neuropathic Symptoms and Signs, CTCAE: Common Terminology Criteria for Adverse Events, EoS: End of Study, ET: Early Termination.

Once a patient is enrolled or randomised, the study site will make every effort to follow the patient for the entire study period. Patients will not be allowed to cross over from one group to another group until the end of the study, however, they can choose to leave the study for any reasons at any time without detriment to the provision or quality of their clinical care. The investigators at each study site will maintain individual records for each patient as source data, which will include a signed copy of informed consent, medical records, laboratory data and other records or notes. All data will be

1
2
3
4
5
6 collected by the independent data management centre. The Japanese Organisation for
7
8
9 Research and Treatment of Cancer (JORTC) Data Center (Japan) and the Improving
10
11 Palliative Care through Clinical Trials (IMPACCT) Trials Coordination Centre
12
13
14 (Australia) will oversee the intra-study data sharing process in each country. The
15
16 clinical data entry, data management and central monitoring will be performed using the
17
18 electric data capture system VIEDOC 4 (PCG Solutions, Sweden) in Japan and
19
20 REDCap (Vanderbilt University, USA) in Australia. An interim analysis will not be
21
22 performed. Audit may take place by JORTC Audit Committee in Japan and by an
23
24 external agency in Australia.
25
26
27
28
29
30
31
32
33
34
35

36 Safety assessments

37
38
39 Investigators must record all AEs in the medical records and web systems. The National
40
41 Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE Ver.4.0)
42
43 ^{27,28} will be used to grade each AE. All AEs are to be followed up continually during
44
45 their course. All serious adverse events (SAEs) must be reported to Osaka City
46
47
48 University Hospital Certified Review Board (CRB) and a Medical Monitor within
49
50
51 Australia, with annual safety reporting to the Human Research Ethics Committee
52
53
54 (HREC), and to investigators in all sites. Participants that are enrolled into the study
55
56
57
58
59
60

1
2
3
4
5
6 will be treated by health care providers properly.
7
8
9

10 11 12 Assessment tools 13

14
15 All the appropriate permissions were obtained for the use for the assessment
16
17
18 instruments.
19
20
21
22

23 24 **Brief Pain Inventory-Short Form (BPI-SF)** 25

26
27 The Brief Pain Inventory – Short Form will be used as it is a brief and easy tool for the
28
29 assessment of pain within both the clinical and research settings. It has been validated in
30
31 both the chronic pain and cancer settings. The numerical rating scale of 0 to 10 is simple
32
33 for participants to use and reflects common clinical assessment of pain ²⁹.
34
35
36
37
38
39
40
41

42 **Global Impression of Change** 43

44
45 The Global Impression of Change is a participant-rated 7- point scale (1-7) that provides
46
47 information about the participants' perception of their overall change in pain since
48
49 commencing the study. This will allow the investigators to compare the pain rating
50
51 using the NRS with participant perception of improvement. The results of this scale
52
53
54 over the study period will assist to determine the clinical significance of any
55
56
57
58
59
60

1
2
3
4
5
6 improvement seen ³⁰.
7
8
9

10 11 12 **Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)** 13

14
15 The LANSS estimates the probability that neuropathic mechanisms contribute to the
16 chronic pain experience in each participant. It has 85% sensitivity for detecting
17 neuropathic pain. It is a seven-item scale including sensory description and
18 examination. A score of ≥ 12 indicates that neuropathic mechanisms are likely to
19 contribute to the participant's pain. It will be used to define a population with
20 neuropathic pain ³¹. The LANSS will be collected to determine eligibility.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2)** 37

38
39 The Short Form McGill Pain Questionnaire 2 (SF-MPQ-2) ³² will be used to examine
40 differences in effects due to pain mechanisms. The SF-MPQ-2 and its Japanese version
41 have been validated in cancer neuropathic pain ³³. It is a 22-item questionnaire covering
42 the domains of superficial and deep spontaneous pain, paroxysmal pain, evoked pain
43 and paresthesia/dysaesthesia. We also used this tool in the pilot study that underpins the
44 current trial ^{15,16} and consider the possibility of effective pain types. This time it will be
45 used to make a comparison for that verification.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Personalised pain goal

The personalised pain goal ³⁴ is a tool used to tailor pain management to individual needs. “Participants are asked to describe on a 0-10 scale, the level/intensity of pain that will allow the patient to achieve comfort in physical, functional, and psychosocial domains” ³⁴ This will be asked by the research nurse or staff at baseline, and may include explanation of terminology. Zero will represent no pain and ten will represent worst pain. This is not a validated tool. We use this scale because some argued that neither between-group difference in mean values nor changes in pain intensity (e.g., absolute or relative values) correctly evaluated the patient’s discomfort.

European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL

The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL will be used for evaluation of patient quality of life. The reliability and validity of the original version ³⁵ and Japanese version ³⁶ have been confirmed.

Hospital Anxiety and Depression Scale (HADS)

1
2
3
4
5
6 The Hospital Anxiety and Depression Scale (HADS) ³⁷ will be used for measurement of
7
8
9 psychiatric symptoms (anxiety and depression) of patients with a physical disease.
10

11
12 HADS is a screening tool that allows assessment based on a small number of items. Its
13
14
15 reliability and validity have been verified internationally ^{37,38}.
16
17

18 19 20 21 **Patient Expectation**

22
23
24 Patient's expectation of a decrease in pain of each patient will be examined as one study
25
26
27 has shown the effect of expectation of pain decrease influenced pain prognosis in cancer
28
29
30 pain ³⁹.
31
32

33 34 35 36 **Australia-modified Karnofsky Performance Status (AKPS)**

37
38
39 The Australia-modified Karnofsky Performance Status (AKPS) ⁴⁰ will be used to assess
40
41
42 performance status. The AKPS is a useful modification of the Karnofsky Performance
43
44
45 Status (KPS) ⁴¹ and validated as an appropriate tool for palliative medicine.
46
47
48
49
50

51 52 **CTCAE/PRO-CTCAE**

53
54 Any new or worse AEs will be evaluated and classified according to CTCAE criteria
55
56
57 ^{27,28} and the Patient-Reported Outcomes version of the Common Terminology Criteria
58
59
60

1
2
3
4
5
6 for Adverse Events (PRO-CTCAE) ⁴². PRO-CTCAE was developed by the National
7
8
9 Cancer Institute (NCI) as an AE assessment system to evaluate patients' subjective
10
11
12 symptoms. Its content validity and psychometric validity have been verified in the
13
14
15 original English version ^{42,43}. Japanese version of the PRO-CTCAE had acceptable
16
17
18 reliability and linguistic ⁴⁴ and psychometric ⁴⁵ validity for common and clinically
19
20
21 important symptoms.
22
23
24
25
26

Interventions

27
28
29
30 All participants will take blinded opaque capsules each morning after breakfast and
31
32
33 bedtime for 14 days. Dose escalation is until day 14 and from day 14 to 21 is a dose de-
34
35
36 escalation period to avoid withdrawal effects. Participants will increase the study drugs
37
38
39 to stage 2 on day 4 and to stage 3 on day 8. Participants will be assessed for AEs during
40
41
42 the study period. If a person experiences mild, moderate, or severe AEs, as classified by
43
44
45 the NCI Criteria, they will be treated symptomatically. If symptoms persist, participants
46
47
48 will continue the previous dose prior to adverse symptoms being noted (or if on the
49
50
51 amount of stage 1 will exit the study). If participants experience unacceptable AEs on:
52
53
54 days 1 - 3 on the stage 1 drug (30mg duloxetine or 50mg pregabalin daily dose) they
55
56
57 will be withdrawn from the study; days 4 - 7 on the stage 2 drug (30mg duloxetine or
58
59
60

1
2
3
4
5
6 150mg pregabalin daily dose) they will continue in the study to day 14 on stage 1 drug
7
8
9 (30mg duloxetine or 50mg pregabalin daily dose); days 8 - 14 on the stage 3 drug (60
10
11
12 mg duloxetine or 300mg pregabalin daily dose) they will continue in the study to day 14
13
14
15 on stage 2 drug (30mg duloxetine or 150mg pregabalin daily dose) . Assessments to
16
17
18 determine net clinical effect will be conducted on day 14. The dose will be tapered
19
20
21 down until the amount of stage 1 (stage 3→2→1 or stage 2→1) and the medication will
22
23
24 be stopped to avoid a discontinuation syndrome, mirroring the schedule for initial
25
26
27 upwards titration (i.e. duloxetine 30mg/pregabalin 150 mg for 4 days, 30mg/50mg for 3
28
29
30 days then cease <from stage 3; days 15-21> or duloxetine 30mg/pregabalin 50mg for 3
31
32
33 days then cease < from stage 2; days 15-17 >). Rescue opioids will be available on an
34
35
36 ‘as needed’ basis, up to eight doses of currently prescribed breakthrough opioid in any
37
38
39 24-hour period. Following cessation of study medications, participants will be reviewed
40
41
42 by their treating clinician regarding any future open label prescribing of the study
43
44
45 medications. If pain is present or re-occurs during the downward titration phase, the
46
47
48 treating clinician should determine the most appropriate pain medication according to
49
50
51 the local standard of care and monitor the patient closely.

52 53 54 55 56 57 **Concomitant therapy** 58 59 60

1
2
3
4
5
6 Concomitantly administered analgesics such as opioids, non-steroidal anti-
7
8
9 inflammatory drugs (NSAIDs), acetaminophen, or other adjuvant analgesics such as
10
11
12 anticonvulsants, antidepressants, antiarrhythmics, N-methyl-D-aspartate (NMDA)
13
14
15 receptor antagonists, and steroids will not be changed during the follow-up period. New
16
17
18 analgesics will not be started. If nausea occurs during the treatment period, use of an
19
20
21 antiemetic will be permitted.
22
23
24
25
26

27 **Study endpoints**

30 **Primary endpoint**

31
32
33 The primary endpoint is a mean difference between study arms of worst pain
34
35
36 intensity over the previous 24 hours at day 14 measured using the BPI items 3.
37
38
39
40
41

42 **Secondary endpoints**

43
44
45 Efficacy will be assessed using the following secondary endpoints: the average pain
46
47
48 intensity (BPI items 5) at days 14 and 21; the worst pain intensity (BPI items 3) at day
49
50
51 21; the SF-MPQ-2 scores; EORTC QLQ-C15-PAL scores; changes in HADS score; and
52
53
54 daily opioid dose (on each day). AEs will also be assessed using NCI CTCAE and
55
56
57 PRO-CTCAE.
58
59
60

1
2
3
4
5
6 Additionally we will calculate percentage of participants with a reduction (BPI-I
7
8
9 items 3) of 1 point; 2 point; > 2 points; 30% and 50% pain decrease from the baseline
10
11
12 on day3, day7 and day14, percentage of participants in whom increase to the maximum
13
14
15 dose is achieved, percentage of participants in whom can achieve personal pain goal,
16
17
18 percentage of participants in whom need to adjust baseline opioids and adjuvant
19
20
21 analgesics, the completion rate of the study medication and procedures, total daily dose
22
23
24 of adjuvant analgesics use (on each day), prospectively sought AEs with the likelihood
25
26
27 of relationship to intervention (toxicity), and health service utilisation-planned and
28
29
30 unplanned contact, investigations, hospitalisations.
31
32
33
34
35

36 **Statistical considerations**

37
38
39 All statistical procedures will be detailed in the statistical analysis plan through a
40
41
42 blinded data review before data fixation, including the handling of missing values and
43
44
45 necessity of sensitivity analysis. For the primary endpoint, the current policy is to
46
47
48 employ observed case analysis when the number of missing observations is very small,
49
50
51 and to employ multiple imputation when there are a certain number of missing
52
53
54 observations and the missing mechanism is considered to be missing at random.
55
56
57
58
59
60

Statistical hypothesis

Comparison of the primary endpoint of the worst pain intensity (BPI items 3) at day 14 between duloxetine groups and pregabalin groups will be conducted using a two-sided Student's t-test at a significance level of 5% according to the intention-to-treat principle. Point estimates and 95% CIs for the difference between two group means will be calculated.

The secondary endpoints of efficacy (BPI items 5, SF-MPQ-2, EORTC QLQ-C15-PAL, HADS, daily opioid dose, and group comparison of worst pain on the BPI-item3 in the previous 24 hours) will be evaluated similarly to the primary endpoint.

Longitudinal changes in BPI-item 3 and BPI-item 5 will be evaluated using mean scores and 95% CIs. The distribution of grades of AEs (NCI CTCAE and PRO-CTCAE) and the incidence of AEs of Grade 3 or higher and of Grade 4 will be determined. Sub-group analyses will be performed to evaluate the difference among various types of peripheral NCP.

Sample size calculation

The difference between group BPI-item 3 on day 14 is assumed to be one point and the standard deviation of the NRS is taken to be 2.0 points^{16, 46, 47}. As there was no consensus

1
2
3
4
5
6 about the minimal clinically important differences in NCP at the planning stage of the
7
8
9 study, we decided to adopt 1-point difference compared to pregabalin as the clinical
10
11
12 significant difference, according to the recommendation of interpreting the clinical
13
14
15 importance of group differences in chronic pain clinical trials ⁴⁶.

16
17
18 Based on our primary outcome, which is worst pain intensity (BPI-item 3) at day 14,
19
20
21 we will estimate 64 participants per group would detect a mean difference of 1.0 (SD 2.0;
22
23
24 80% power with a two-sided significance level of 0.05 for comparison).

25
26
27 Considering withdrawal and drop-out of 20%, we plan to recruit 160 participants into
28
29
30 the study.

31 32 33 34 35 36 **Ethical issues**

37
38
39 All patients will be required to provide written informed consent. The study will be
40
41
42 performed in accordance with the Declaration of Helsinki, the Australian Good Clinical
43
44
45 Practice, and the Japan's Clinical Trials Act. The protocol was approved by the Osaka
46
47
48 City University Hospital CRB and the Scientific Advisory Committee (Palliative Care
49
50
51 Clinical Studies Collaborative (PaCCSC)) within Australia with annual safety reporting
52
53
54 to the approving HRECs. This trial has been registered with the clinical trials registries
55
56
57 within both Japan and Australia. Modifications in the study protocol will be
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

communicated to approving CRB (Japan) and HRECs (Australia). Each Ethics Committee or Institutional Review Board will review informed consent materials given to participants and adapt according to their own institution's guidelines.

Discussion

To our knowledge, the results of the recent systematic review ⁴⁸ has shown the low quality of currently available evidence on the effectiveness of adjuvant analgesics in the treatment of cancer pain and our subsequent clinical trial ¹⁶ shows the low-quality evidence of adjuvant analgesics for opioid refractory NCP as well. There has been no RCT of the analgesic efficacy of oral duloxetine for the management of opioid refractory NCP as a first line treatment.

In our planned trial, the use of a randomised, double-blind, two-parallel arm design, is the most appropriate design to demonstrate the efficacy of a new therapy. Our findings using this approach may also allow international recommendations to be updated. We also considered a crossover design, but a parallel design was finally chosen, given that the crossover design has several limitations, especially in this population ⁴⁹, namely; the treatment might have carryover effects and alter the response to subsequent treatments; and palliative patients may not be in a comparable condition

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

at the start of the crossover trial treatment period.

Several issues related to the content of the trial require discussion. There will be five major concerns: (i) the heterogeneity of causes of NCP, (ii) risk of drug-drug interactions and masking/confounding of the true effect of the study intervention, (iii) the choice of the primary endpoint, (iv) necessity of a placebo group, and (v) the dose schedule of each drugs.

First, to address the heterogeneous causes of NCP, we excluded patients with CIPN and central NP, and targeted patients with NCP non-responsive or intolerant to opioid therapy, but the trial might still be criticised due to combination of various peripheral NCPs in one study. Narrower criteria are theoretically possible, but accrual of patients who meet these criteria is likely to be difficult. Furthermore, in palliative care field, a framework for classifying research subpopulations to which the research findings are being applied by clinicians, health planners, and funders in real-world settings has been suggested⁵⁰. We thus decided to include various types of peripheral NCP in the study, and sub-group analyses will be performed.

Second, although drugs with major drug-drug interactions with duloxetine or pregabalin (e.g., contraindicated) will be excluded, continuation of the other adjuvant analgesics might cause the risk of moderate-minor drug-drug interactions. The

1
2
3
4
5
6 possibility of masking/confounding of the true effect of the study intervention cannot be
7
8
9 completely ruled out, however, randomisation will allow for some degree of balance
10
11
12 between the groups.
13

14
15 Third, the primary endpoint is the difference in worst pain intensity score at day 14
16
17 between two groups. Although we had acknowledged that the average pain intensity is
18
19 adopted by many clinical trials about NCP⁵¹, including three RCTs^{8,9,16} in patients with
20
21 NCP, some authors recommend worst pain intensity in the last 24 hours as primary
22
23 endpoints because it satisfies most key recommendations in the draft guidance¹⁸.
24
25
26
27
28

29
30 Furthermore, to evaluate chronic pain, especially considering the nature of NCP in this
31
32 setting, we concluded that it is better to use the “worst pain intensity in the last 24
33
34 hours” as the primary endpoint after discussion among the members of the study’s
35
36 steering committee.
37
38
39
40

41
42 Fourth, although we discussed the need for a placebo arm, gabapentinoids
43
44 (gabapentin and pregabalin) are one of the most widely used treatments for NCP (not
45
46 for just cancer pain, nor CIPN). Phase III studies^{8,10} revealed moderate analgesic effects
47
48 of gabapentinoids (gabapentin and pregabalin) compared with placebo in combination
49
50 with opioids for NCP (not for just cancer pain, nor CIPN). From the results of these 2
51
52 RCTs^{8,10}, we concluded that it was no longer ethical to use a placebo arm.
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Finally, the following dose titration schedule has been devised to maximize the
7
8
9 likelihood of benefit while minimising the risk of AEs. The participant will commence
10
11 duloxetine or pregabalin at 30mg and 50mg respectively and will be titrated according
12
13 to response in increments of cessation to a maximum of 60mg (duloxetine) and 300mg
14
15 (pregabalin). As the starting dose differs between Australia and Japan, it was necessary
16
17 to determine a uniform dose for the international study. The starting dose of duloxetine
18
19 in Japan is 20 mg in the setting for palliative care ⁵², while in the West it is usually 30
20
21 mg or 60 mg. We chose 30 mg for the starting dose of duloxetine because we assumed
22
23 that it was also tolerable for Japanese patients. In the same setting, the starting dose of
24
25 pregabalin in Japan is 50 mg ⁵², while in the West it is usually 25-100mg from the
26
27 results of recent systematic review and meta-analysis ¹³. Taking these results into
28
29 consideration, we assume that starting 150 mg pregabalin is not tolerable and 50 mg is
30
31 safe for patients in both countries. Dworkin et al. conducted a systematic review of
32
33 pharmacologic management of NCP and made the recommendations for maximum
34
35 dosing ⁵³ and according to the National Comprehensive Cancer Network (NCCN)
36
37 guideline of adult cancer pain ² we have defined initiation dose and maximum dose of
38
39 both drugs.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55
56
57 Moreover, we set a dose decrement titration periods instead of doing key open to
58
59
60

1
2
3
4
5
6 avoid a discontinuation syndrome of each drug and to keep scientific reliability.
7
8

9 Therefore, the planned international double-blind multi-centre RCT will be the first to
10
11 evaluate the efficacy and safety of duloxetine and pregabalin treatment in patients
12
13 suffering from well-defined NCP refractory to opioids, and the results of the trial will
14
15 help to clarify the first-line standard treatment for NCP.
16
17
18
19
20
21
22
23

24 **Trial status**

25
26
27 The trial opened in January 2020. At the time of manuscript submission (February
28
29 2021), twenty-one patients have been randomised. We expect to complete the
30
31 recruitment by September 2022 and to finish this trial by March 2023.
32
33
34
35
36
37
38

39 **Confidentially**

40
41
42 Data will be retained in accordance with the Japanese Clinical Research Act and the
43
44 Australian regulations for Good Clinical Practice. Participants will be allocated a unique
45
46 identification (ID) number at entry. The master list linking participant personal
47
48 information and ID number will be maintained in a separate locked cabinet and
49
50 password-protected hard drive at each institution. Data will be analysed by ID number
51
52
53
54
55
56
57 only. Records will be retained for 15 years after study completion and then destroyed by
58
59
60

1
2
3
4
5
6 the data centre.
7
8
9

10 11 12 **Dissemination**

13
14
15 The results of this trial will be submitted for publication in international peer-reviewed
16
17 journals and the key findings presented at conferences. Participants will be informed of
18
19 the results of the trial by the investigators. Authorship will be ascribed in accordance
20
21 with the International Committee of Medical Journal Editors guidance.
22
23
24
25
26
27
28
29

30 31 **Data Sharing Statement**

32
33 Immediately after the publication of the primary results, de-identified individual
34
35 participant data that underlie the results reported in the article(s) and other documents
36
37 (study protocol and statistical analysis plan) will be available for any purpose, only if
38
39 approved by JORTC Independent Data Monitoring Committee (IDMC) and the Cancer
40
41 Symptom Trials (CST) Scientific Advisory Committee.
42
43
44
45
46
47
48
49
50

51 52 **Access to data**

53
54 JORTC Data Center and JORTC Independent Data Monitoring Committee have access
55
56 to the final trial dataset. There is no contractual agreement regarding investigators'
57
58
59
60

1
2
3
4
5
6 access restrictions on dataset.
7
8
9

10 11 12 **Declarations**

13
14
15 The protocol was approved by the Osaka City University Hospital Certified Review
16
17
18 Board and South Western Sydney Local Health District Human Research Ethics
19
20
21 Committee (Australia). Informed consent for participation in the trial will be obtained
22
23
24 from all patients.
25
26
27
28
29

30 31 **Patient and Public Involvement**

32
33 The invaluable contribution of patients and caregivers are recognised by ensuring that
34
35
36 all research undertaken considers patients and caregivers experience and perspectives.
37
38
39 Patients and caregivers' representatives were actively involved in all aspects of our
40
41
42 research including the design, implementation, evaluation, and dissemination of this
43
44
45 randomised control clinical trial. As a member of the protocol investigator team, the
46
47
48 patients and caregivers' representative ensure that the physical and emotional wellbeing
49
50
51 of patients and caregivers were taken into consideration when planning this clinical trial
52
53
54 and implementing the result findings into practice.
55
56
57
58
59
60

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the following grant: 2017-2019 Japan Agency for Medical Research and Development (AMED) award (19ck0106328h0003, Innovative Clinical Cancer Research) and will be supported by the following grants: 2020-2024 Australian Government National Health and Medical Research Council Clinical Trials and Cohort Studies funding (NHMRC: APP1188023) and 2020-2022 Japan Agency for Medical Research and Development (AMED) award (20ck0106603h9901, Innovative Clinical Cancer Research). The entire research organization has no conflicts of interest to declare.

Sponsor detail

Division of Cancer Research Department of Research Promotion

Japan Agency for Medical Research and Development

22F Yomiuri Shimbun Bldg. 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

Phone: +81-3-6870-2221

1
2
3
4
5
6 Fax: +81-3-6870-2244
7
8
9

10
11
12 University of Technology Sydney (UTS)
13

14
15 Cancer Symptom Trials (CST), IMPACCT
16

17
18 Broadway, ULTIMO, NSW 2007, Australia
19

20
21 Phone: +61 2 9514 2000
22

23
24 CST@uts.edu.au
25
26
27
28
29

30 Abbreviations

31
32
33 NCP: Neuropathic cancer pain; RCTs: randomized controlled trials; BPI: Brief pain
34 inventory; LANSS: the Leeds assessment of neuropathic symptoms and signs; CIPN:
35
36 Chemotherapy-Induced Peripheral Neuropathy; TCA: Tricyclic Antidepressant; SNRI:
37
38 Serotonin & Norepinephrine Reuptake Inhibitors; AE: Adverse event; NNT: number
39
40 needed to treat; AKPS: Australia-modified Karnofsky Performance Status; KPS:
41
42 Karnofsky Performance Status; IASP: International Association for the Study of Pain;
43
44
45
46
47
48
49 NRS: Numerical Rating Scale; HADS: Hospital Anxiety and Depression Scale; JORTC:
50
51
52 Japanese Organization for Research and Treatment of Cancer; IMPACCT: The
53
54
55
56
57 Improving Palliative Care through Clinical Trials; AE: Adverse event; CTCAE:
58
59
60

1
2
3
4
5
6 Common Terminology Criteria for Adverse Events; SAEs: Serious adverse events;
7
8
9 CRB: Certified Review Board; HREC: Human Research Ethics Committee; BPI-SF:
10
11
12 Brief Pain Inventory-Short Form; SF-MPQ: Short-Form McGill Pain Questionnaire;
13
14
15 EORTC: European Organization for Research and Treatment; PRO-CTCAE: Patient-
16
17
18 Reported Outcomes version of the Common Terminology Criteria for Adverse Events ;
19
20
21 NCI: National Cancer Institute; NSAIDs: Non-Steroidal Anti-Inflammatory Drugs;
22
23
24 NMDA: N-methyl-D-aspartate; PaCCSC: Palliative Care Clinical Studies
25
26
27 Collaborative; NCCN: National Comprehensive Cancer Network; IDMC: Independent
28
29
30 Data Monitoring Committee; CST: Cancer Symptom Trials; AMED: Japan Agency for
31
32
33 Medical Research and Development; NHMRC: Australian Government National Health
34
35
36 and Medical Research Council; UTS: University of Technology Sydney
37
38
39
40
41

42 Authors' contributions

43
44
45 HM, KC, BF, LB, HI, YM, HH, KA, JL, BL, PA, SK, NF, TM, ML, MA, ES, SI, JP,
46
47
48 AK, and DC participated in the design of the study. SO, TY, designed the statistical
49
50
51 analysis plan. All authors contributed to writing and revising the manuscript critically,
52
53
54 and all gave their final approval of the version to be published.
55
56
57
58
59
60

Acknowledgements

We are grateful for support from the Japan Agency for Medical Research and Development (AMED), Grant-in-Aid for Scientific Research, and the Australian Government National Health and Medical Research Council (NHMRC) Clinical Trials and Cohort Studies funding. The authors thank in advance all the patients, investigators, patients and caregivers' representatives and institutions involved in this study.

1. Jongen JL, Huijsman ML, Jessurun J, et al. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. *Journal of pain and symptom management*. 2013;46(4):581-90.e1.
2. Swarm RA, Paice JA, Anghelescu DL, et al. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2019;17(8):977-1007.
3. Cruccu G, Truini A. A review of Neuropathic Pain: From Guidelines to Clinical Practice. *Pain Ther*. 2017 Dec;6(Suppl 1):35-42. doi: 10.1007/s40122-017-0087-0.
4. https://www.awmf.org/fileadmin/user_upload/Leitlinien/128_D_Ges_fuer_Palliativmedizin/128-001OLkengl_S3_Palliative_care_2021-03.pdf (Germany). Accessed September 24, 2021.
5. Piano V, Verhagen S, Schalkwijk A, et al. Treatment for neuropathic pain in patients with cancer: comparative analysis of recommendations in national clinical practice guidelines from European countries. *Pain Pract*. 2014 Jan;14(1):1-7. doi: 10.1111/papr.12036.
6. Piano V, Schalkwijk A, Burgers J, et al. Guidelines for neuropathic pain management in patients with cancer: a European survey and comparison. *Pain Pract*. 2013 Jun;13(5):349-57. doi: 10.1111/j.1533-2500.2012.00602.x.

- 1
2
3
4
5
6
7 7. Attal N, Cruccu G, Baron R, et al. European Federation of Neurological Societies.
8
9 EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010
10
11
12 revision. *Eur J Neurol*. 2010 Sep;17(9):1113-e88. doi: 10.1111/j.1468-
13
14
15 1331.2010.02999.x.
16
17
- 18
19 8. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a
20
21 randomized controlled trial from the Gabapentin Cancer Pain Study Group. *Journal*
22
23
24 of clinical oncology: official journal of the American Society of Clinical Oncology.
25
26
27 2004;22(14):2909-17.
28
29
- 30
31 9. Dou Z, Jiang Z, Zhong J. Efficacy and safety of pregabalin in patients with
32
33 neuropathic cancer pain undergoing morphine therapy. *Asia Pac J Clin Oncol*. 2017
34
35
36 Apr;13(2):e57-e64. doi: 10.1111/ajco.12311.
37
38
- 39
40 10. Mishra S, Bhatnagar S, Goyal GN, et al. A comparative efficacy of amitriptyline,
41
42 gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized
43
44
45 double-blind placebo-controlled study. *Am J Hosp Palliat Care*. 2012;29:177-82.
46
47
- 48
49 11. Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in
50
51
52 neuropathic cancer pain in patients on morphine therapy: a randomized placebo-
53
54
55 controlled, double-blind crossover study. *Tumori*. 2002;88(3):239-42.
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
12. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. *JAMA*. 2013;309:1359-67.
13. Kane CM, Mulvey MR, Wright S, et al. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. *Palliat Med*. 2018;32:276-286.
14. Matsuoka H, Makimura C, Koyama A, et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. *Anticancer Res*. 2012;32:1805-10.
15. Matsuoka H, Iwase S, Miyaji T, et al. Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study. *Supportive Care in Cancer*. 2020 Jun;28(6):2931-2939. doi: 10.1007/s00520-019-05138-9.
16. Matsuoka H, Iwase S, Miyaji T, et al. Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08). *J Pain Symptom Manage*. 2019 Jun 26. pii: S0885-3924(19)30364-1. doi: 10.1016/j.jpainsymman.2019.06.020.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17. Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. *Pain*. 2016;157:1599-606.
18. Atkinson TM, Mendoza TR, Sit L, et al. The brief pain inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. *Pain Med* 2010;11:337-46.
19. Mulvey MR, Boland EG, Bouhassira D, et al. Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles. *Br J Anaesth*. 2017 ;119(4):765-774. doi: 10.1093/bja/aex175.
20. Therneau TM. How many stratification factors are "too many" to use in a randomization plan? *Control Clin Trials*. 1993;14(2):98-108. doi: 10.1016/0197-2456(93)90013-4.
21. Smith SM, Dworkin RH, Turk DC, et al. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. *Pain*. 2020;161(11):2446-2461. doi: 10.1097/j.pain.0000000000001952.
22. Gaudreau JD, Gagnon P, Harel F, Roy MA, Tremblay A. Psychoactive medications and risk of delirium in hospitalized cancer patients. *J Clin Oncol*. 2005 20;23(27):6712-8. doi: 10.1200/JCO.2005.05.140.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23. Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. *J Pain Symptom Manage.* 1999;18(3):174-9. doi: 10.1016/s0885-3924(99)00060-3.
24. Brown LF, Kroenke K, Theobald DE, Wu J, Tu W. The association of depression and anxiety with health-related quality of life in cancer patients with depression and/or pain. *Psychooncology.* 2010;19(7):734-41. doi: 10.1002/pon.1627.
25. Saquib N, Saquib J, Ioannidis JP. Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic study. *BMJ.* 2013;347:f4313. doi: 10.1136/bmj.f4313.
26. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ.* 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869.
27. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common terminology criteria for adverse events version 4.03 (CTCAE). 2010. Available from: <https://evs.nci.nih.gov/ftp1/CTCAE/About.html>. Accessed February 10, 2018.
28. Japan Clinical Oncology Group. Common terminology criteria for adverse events version 4.0 (CTCAE v4.0-JCOG). Available

1
2
3
4
5
6 from:http://www.jcog.jp/doctor/tool/CTCAEv4J_20170912_v20_1.pdf. Accessed
7
8
9 February 10, 2018.

- 10
11
12 29. Cleeland CS. Measurement of pain by subjective report. In: Chapman CRL, J.D.,
13
14 editor. *Advances in Pain Research and Therapy. Volume 12: Issues in Pain*
15
16 *Measurement*. New York: Raven Press; 1989. p. 391-403.
17
18
19
20
21 30. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. Clinical importance
22
23 of changes in chronic pain intensity measured on an 11-point numerical pain rating
24
25 scale. *Pain*. 2001;94(2):149-58.
26
27
28
29
30 31. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms
31
32 and signs. *Pain*. 2001;92(1-2):147-57.
33
34
35
36 32. Dworkin RH, Turk DC, Revicki DA, et al: Development and initial validation of an
37
38 expanded and revised version of the Short-form McGill Pain Questionnaire (SF-
39
40 MPQ-2). *Pain* 144:35-42, 2009
41
42
43
44
45 33. Maruo T, Nakae A, Maeda L, et al. Validity, reliability, and assessment sensitivity
46
47 of the Japanese version of the short-form McGill pain questionnaire 2 in Japanese
48
49 patients with neuropathic and non-neuropathic pain. *Pain Med* 2014;15:1930-7.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 34. Dalal S, Hui D, Nguyen L, et al. Achievement of personalized pain goal in cancer
8
9 patients referred to a supportive care clinic at a comprehensive cancer center.
10
11
12 Cancer. 2012;118(15):3869-77.
13
14
- 15 35. Groenvold M, Petersen MA, Aaronson NK, et al: The development of the EORTC
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
36. Miyazaki K, Suzukamo Y, Shimozuma K, et al: Verification of the psychometric
properties of the Japanese version of the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire Core 15 palliative
(EORTCQLQ-C15-PAL). Qual Life Res 21: 335-340, 2012.
37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr
Scand 1983;67:361-70.
38. Kugaya A, Akechi T, Okuyama T, et al. Screening for psychological distress in
Japanese cancer patients. Jpn J Clin Oncol 1998;28:333-8.
39. Matsuoka H, Yoshiuchi K, Koyama A, et al. Expectation of a Decrease in Pain
Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of
Response to Morphine. Int J Behav Med. 2017 Aug;24(4):535-541. doi:
10.1007/s12529-017-9644-5.

- 1
2
3
4
5
6
7 40. Abernethy AP, Shelby-James T, Fazekas BS, et al. The Australia-modified
8
9 Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary
10
11 palliative care clinical practice. *BMC Palliat Care*. 2005 Nov 12;4:7. doi:
12
13 10.1186/1472-684X-4-7.
14
15
16
17
18 41. Karnofsky D, Abelmann W, Craver L, Burchenal J. The use of nitrogen mustard in
19
20 the palliative treatment of cancer. *Cancer*. 1948;1:634–656
21
22
23
24 42. Hay JL, Atkinson TM, Reeve BB, et al. NCI PRO-CTCAE Study Group. Cognitive
25
26 interviewing of the US National Cancer Institute's Patient-Reported Outcomes
27
28 version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
29
30 *Qual Life Res* 2014 Feb;23(1):257-69. doi: 10.1007/s11136-013-0470-1.
31
32
33
34
35
36 43. Dueck AC, Mendoza TR, Mitchell SA, et al. National Cancer Institute PRO-
37
38 CTCAE Study Group. Validity and Reliability of the US National Cancer Institute's
39
40 Patient-Reported Outcomes Version of the Common Terminology Criteria for
41
42 Adverse Events (PRO-CTCAE). *JAMA Oncol* 2015 Nov;1(8):1051-9. Erratum in:
43
44 *JAMA Oncol*. 2016 Jan;2(1):146.
45
46
47
48
49
50
51 44. Miyaji T, Iioka Y, Kuroda Y, et al.: Japanese translation and linguistic validation of
52
53 the US National Cancer Institute's Patient-Reported Outcomes version of the
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 Common Terminology Criteria for Adverse Events (PRO-CTCAE). *J Patient Rep*
8
9
10 Outcomes. 2017;1(1):8. doi: 10.1186/s41687-017-0012-7.
11
- 12 45. Kawaguchi T, Azuma K, Sano M, et al: The Japanese version of the National
13
14
15 Cancer Institute's patient-reported outcomes version of the common terminology
16
17
18 criteria for adverse events (PRO-CTCAE): psychometric validation and discordance
19
20
21 between clinician and patient assessments of adverse events. *J Patient Rep*
22
23
24 Outcomes. 2017;2(1):2. doi: 10.1186/s41687-017-0022-5.
25
- 26 46. Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance
27
28
29 of group differences in chronic pain clinical trials: IMMPACT recommendations.
30
31
32
33 *Pain*. 2009 Dec;146(3):238-44. doi: 10.1016/j.pain.2009.08.019.
34
- 35 47. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain
36
37
38
39 in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015;14:162–
40
41
42 73.doi:10.1016/S1474-4422(14)70251-0.
43
- 44 48. van den Beuken-van Everdingen MH, de Graeff A, Jongen JL, et al.
45
46
47
48
49 Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant
50
51
52 Analgesics, a Systematic Review. *Pain Pract*. 2017 Mar;17(3):409-419. doi:
53
54
55 10.1111/papr.12459.
56
57
58
59
60

- 1
2
3
4
5
6
7 49. Senn SS. Cross-over trials in clinical research. Chichester: John Wiley & Sons,
8
9 2002.
10
11
12 50. Currow DC, Wheeler JL, Glare PA, Kaasa S, Abernethy AP. A framework for
13
14 generalizability in palliative care. *J Pain Symptom Manage* 2009;37:373e386.
15
16
17 51. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. *Cochrane*
18
19 *Database Syst Rev* 2013;29:8 CD006146.
20
21
22 52. Matsuoka H, Tagami K, Ariyoshi K, et al. Attitude of Japanese palliative care
23
24 specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to
25
26 opioid therapy: a nationwide cross-sectional survey. *Jpn J Clin Oncol*. 2019 May
27
28 1;49(5):486-490. doi: 10.1093/jjco/hyz002.
29
30
31 53. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of
32
33 neuropathic pain: Evidence-based recommendations. *Pain*. 2007;132:237-51.
34
35
36
37
38
39
40
41
42
43
44

45 **Figure Legends**

46
47
48 Figure 1. Flow chart of the procedures in the study. Participants will be randomized (1:1
49
50 allocation ratio) into the duloxetine group or the pregabalin group.
51
52
53
54
55
56
57
58
59
60

Eligibility Criteria
 BMJ Open

- Patients with diagnoses of cancer and neuropathic pain
- Patients with a worst pain score of 4 or greater on BPI-item-3
- Neuropathic Pain on LANSS 12 or greater
- Patients who are currently receiving opioids to the maximum tolerated dose or titration to at least a dose of 60mg/day oral morphine equivalent dose

Exclusion criteria

- Chemotherapy-Induced Peripheral Neuropathy
- Spinal cord compression
- Contraindication for duloxetine or pregabalin
- Taking gabapentinoids or duloxetine within 2 weeks.
- Taking SSRI or SNRI or MAOIs for any reason.
- New chemotherapy started within 14 days of baseline
- Clinical trial involving a new chemical entity within 4 weeks prior to study entry.
- Patients with renal failure and hepatic failure

Inclusion (within 1 week before study treatment start):
 Randomisation, Liver function, eGFR, BPI-item 3, BPI-item 5
 HADS, AKPS, LANSS

Duloxetine group
 Duloxetine 30-60 mg/day
 for 14 days

Pregabalin group
 Placebo 50-300 mg/day
 for 14 days

Day0 (Pre-treatment start):
 BPI-SF, SF-MPQ-2, EORTC- QLQ-C15 Pal, Pain Expectation,
 PRO CTCAE, Personalised pain goal, and CTCAE

Day3 (3 days after treatment start): AKPS, CTCAE
Day4 (4 days after treatment start): Global impression of change

Day7 (7 days after treatment start): AKPS, CTCAE
Day8 (8 days after treatment start): Global impression of change, PRO-CTCAE

Day14 (14 days after treatment start):
 Liver function, eGFR, BPI-SF, SF-MPQ-2, EORTC- QLQ-C15 Pal, HADS, Global impression of change,
 PRO-CTCAE, CTCAE and Patient interview (if consented)

Day21 (21 days after treatment start):
 Global impression of change, PRO-CTCAE, and CTCAE

Eligibility, Day1-13,15-21:
 BPI-item 3
 BPI-item 5

Day 1-21:
 Patients' diary
 Opioid consumption

Fig.1. Flow chart of the procedures in the study